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Abstract
This study assessed cost-effectiveness of pharmacogenomics (PGx)-based warfarin,
apixaban and rivaroxaban compared to standard warfarin therapy for atrial fibrillation
(AF) patients in Canada. A decision-analytic Markov model was developed to compare
lifetime costs and quality-adjusted life years (QALYs) from the public healthcare payer
perspective. The parameters applied in the model were derived from published literature
and some costs from the ICES databases. The results were summarized in terms of the
incremental cost-effectiveness ratio (ICER). Compared to standard warfarin, PGx-based
warfarin care had an ICER of 17,727/QALY and apixaban had an ICER of
$64,853/QALY gained. Apixaban dominated rivaroxaban. The probabilistic sensitivity
analysis showed that apixaban, rivaroxaban, PGx-based warfarin and standard warfarin
were cost-effective at some willingness-to-pay (WTP) thresholds. Specifically, PGxbased warfarin therapy had a higher probability of being cost-effective than apixaban
(51.5% vs 14.1%) at a WTP threshold of $50,000/QALY. At a WTP threshold of
$150,000/QALY, apixaban had the highest probability of being cost-effective than PGxbased warfarin (70.1% vs 5.7%). We found that apixaban offers the best balance between
efficacy and safety and has a high probability of being cost-effective for AF patients in
Canada at a WTP threshold of $150,000/QALY.
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Summary for Lay Audience
Atrial fibrillation (AF) is a condition defined by the presence of irregular rapid
heartbeats. Patients with AF have been commonly treated by a blood thinner
(anticoagulant) called warfarin to reduce the risk of stroke. However, rigorous monitoring
of the blood thinning effect is required to avoid adverse events such as stroke and/or
bleeding from inappropriate warfarin dosing. The trial and error approach of current
clinical practice for warfarin dosing involves routine blood tests and poses an increased
risk of adverse events during the initial dose adjustment period. Warfarin-related adverse
events entail a substantial burden on patients’ health and the healthcare system. In
comparison, pharmacogenomic-based (PGx) warfarin therapy adjusts the drug dose
according to the inherent genetic differences of AF patients and has been shown to reduce
risk of adverse events. A new class of drugs for AF therapy are called direct oral
anticoagulants (DOACs), and offer several advantages over warfarin. For example,
apixaban and rivaroxaban are now funded by the Ontario Ministry of Health and longterm care (MOHLTC). DOACs have a predictable pharmacokinetic and dose response,
do not require continuous monitoring, have increased effectiveness in reducing the risk of
stroke and embolism and are associated with decreased risk of bleeding. However, PGxbased warfarin entails an upfront cost for genetic testing, while the medication cost for
DOACs is more than twice than that of warfarin. This cost-effectiveness analysis
compares the lifetime costs and benefits incurred under each treatment strategy from the
MOHLTC perspective. We found that PGx-based warfarin care as well as apixaban and
rivaroxaban improved the health of AF patients by reducing the risk of ischemic strokes
and intracranial bleeding as compared to standard warfarin, yet these alternative
treatments also increased lifetime costs when compared to standard warfarin. PGx-based
warfarin led to a small increase in QALYs and large increase in costs. Among the
DOACs, apixaban treatment resulted in the highest health benefit and dominated
rivaroxaban. The results of this study were sensitive to treatment effectiveness and should
be interpreted with caution.
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Chapter 1 - Introduction
Atrial fibrillation (AF) is one of the most common cardiac arrhythmias among seniors,
affecting approximately 300,000 Canadians (1). In Canada, AF accounted for about 2.6%
of all acute hospital admissions and about 5.6% of all hospitalizations from 2007-2008
(2). In Ontario, about 193 per 100,000 hospitalizations and about 231 per 100,000
emergency visits were directly attributed to atrial fibrillation (2). Patients with AF
experience high morbidity and mortality because the arrhythmia increases the risk of
stroke and death by 3-5-fold and more than 3.5-fold respectively, when compared to the
general population (3). In addition, nearly 50% of AF-related stroke patients are
discharged with severe disability (modified Rankin Score, mRS=3-5)1 and left with
complications ranging from needing assistance with daily activities of living to requiring
24/7 nursing and long-term care (4,5). With an aging population, the prevalence of AF is
expected to increase. The lifetime risk of AF is 1 in 4 at the age of 40 and the incidence
doubles with each decade of life in both males and females (6).

1.1

Pathophysiology of atrial fibrillation

Atrial fibrillation is a condition of the heart. The human heart is divided into four
chambers: two atria and two ventricles. In a healthy heart, cardiovascular contractions
are coordinated by neural pacemaker cells within the sinoatrial node such that the
ventricles contract after the atria finish contracting. However, in the case of AF,
dysfunctional pacemaker cells produce uncoordinated cardiovascular contractions such
that an irregular, and often rapid, heartrate develops. The term used to describe this type
of arrhythmia is tachycardia. Patients displaying such an arrhythmic activity of the atria
suffer from atrial fibrillation.

1

The modified Rankin Score is a standardized instrument that measures the degree of disability,
dependence in function and stroke severity at hospital discharge (4).
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1.2

Atrial fibrillation burden on patients and the
healthcare system

If untreated, AF is often accompanied by symptoms such as rapid heart rate, palpitations,
chest discomfort, shortness of breath and chest pain (7). In addition, stroke is a
complication of untreated AF. The irregular atrial contractions decrease the efficiency
with which blood can be pumped out of the heart. Blood begins to pool in the atria, which
increases the risk of blood clot or thrombus formation. This can lead to stroke (if the
thrombus clogs a blood vessel leading to the brain), systemic embolism (if the thrombus
clogs a systemic blood vessel), myocardial infarction (if the thrombus clogs a coronary
artery) and even death.
AF also imposes a huge financial strain on Canadian hospitals. From 2007-2008, the cost
of AF-related hospital care was about $815 million in Ontario (2). About $710 million
can be attributed to acute hospital care, $32 million to same-day operations and $73
million to emergency department visits (2). On average, AF patients stayed in the
hospital for 5.7 days, costing the Canadian healthcare system $8,148 (2010 CAD) per
hospitalization. However, hospitalizations for whom AF was listed as a comorbidity were
even more costly. The overall cost for AF-related complications was found to be about
$558 million (2010 CAD), constituting 69% of the total hospital care expenses. As noted
earlier, stroke is a serious complication of AF. In Ontario, AF-related ischemic stroke or
transient ischemic attack had the longest average length of hospital stay (20.2 days) with
an average cost of $19,113 (2010 CAD) per admission. Thus, AF and AF-related
complications entail substantial costs to Canadian hospitals. The high AF-related
hospitalization risks and costs can be averted through several existing therapeutic
interventions, such as long-term anticoagulation therapy. However, different
anticoagulation treatments vary in terms of clinical effectiveness and costs.

1.3

Atrial fibrillation management strategies

Several oral anticoagulation therapies are available to mitigate the risks of atrial
fibrillation complications (8). The CHADS2 score is a validated and frequently used
prognostic model that incorporates patient age (>75 years) and comorbidities such as
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history of hypertension, congestive heart failure, diabetes and stroke or TIA and estimates
patients’ risk of thromboembolism without anticoagulation therapy. In general,
anticoagulation therapy is recommended for patients with a CHADS 2 score ≥1 (9). Oral
anticoagulants prevent formation of blood clots by inhibiting blood clotting factors in the
clotting cascade (8). Until recently, warfarin (commercially known as Coumadin) was
commonly prescribed drug to manage AF. However, achieving the drug’s therapeutic
anticoagulation effect is challenging because warfarin’s pharmacological response is
highly variable in patients due to clinical and genetic factors. As such, two strategies
emerged to improve the clinical utility of the standard warfarin therapy:
pharmacogenomics (PGx)-based warfarin care and direct oral anticoagulants (DOACs).
PGx-based warfarin care sought to optimize warfarin therapy through a patient-centered
genotype-guided drug dosing method (10). DOACs, such as apixaban and rivaroxaban,
were developed to achieve safer and more efficacious anticoagulation compared to
standard warfarin therapy without a need for routine monitoring (11). The advantages and
disadvantages of each treatment strategy are described in the following subsections.

1.3.1 Standard warfarin care
Until recently, warfarin, commercially known as Coumadin, was one of the most
commonly prescribed drugs to manage AF (12). Warfarin acts by indirectly inhibiting the
vitamin K-dependent clotting mechanism (13). Under normal circumstances, blood clots
when an enzyme called vitamin K epoxide reductase (VKORC1) generates a pool of
reduced vitamin K, which in turn activates clotting factors II, VII, IX and X. Warfarin
prevents this generation of reduced vitamin K by inhibiting VKORC1, and thus,
impairing the activation of vitamin K-dependent blood clotting factors. For patients with
AF, decreased blood clotting capacity was shown to reduce the risk of stroke (8).
However, warfarin’s mechanism of action also increases the risk of adverse drug
reactions such as hemorrhages, particularly with higher drug doses (8). On the other
hand, drug doses that are too low may not be effective in reducing the risk of ischemic
stroke among patients with AF (8).
Consequently, warfarin dose requirements among patients are highly variable. A narrow
therapeutic range must be achieved using regular blood monitoring and guided by an
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international normalized ratio (INR)2 of 2 to 3 to ensure the correct dose for each patient
(8). This is a tedious trial-and-error process.
Anticoagulation therapy with warfarin has been shown to significantly reduce the risk of
stroke among patients with AF as compared to no anticoagulation or antiplatelet therapy
(14). Due to the high efficacy, warfarin anticoagulation had been the gold standard for
AF treatment for decades. A meta-analysis by Hart et al. (2007) reported that doseadjusted warfarin therapy can be as much as 64% effective in reducing the risk of stroke
for patients with AF as compared to no anticoagulation therapy (14). Dose-adjusted
warfarin therapy is superior in reducing the risk of stroke compared to antiplatelet
therapy with aspirin alone (Relative Risk Reduction (RRR) 37%, 95% confidence
interval (CI) = 23%, 48%) and combination therapy of aspirin and clopidogrel (RRR,
40%, 95% CI=18%, 56%). Not only is warfarin therapy effective in reducing the risk of
ischemic stroke, it is also inexpensive as a monthly supply of warfarin costs anywhere
between $5 and $8 (2011 CAD) (15).
Although standard warfarin therapy is effective compared to no treatment, it has several
caveats. The standard trial and error approach to determine the therapeutic warfarin dose
for each patient is clinically challenging. It requires routine patient monitoring, including
reiterative blood testing with subsequent dose adjustments to achieve the narrow
therapeutic window of an INR ranging from 2 to 3 (8). Moreover, the effectiveness of
warfarin therapy in observational studies has been found to be much lower; a therapeutic
range (INR 2-3) in patients has been only observed 58% of the time. In addition, during
the initial dose adjustment period, there is an increased risk of adverse events;
subtherapeutic dosing can lead to stroke and supratherapeutic dosing can cause
hemorrhage. According to a meta-analysis, standard warfarin therapy has been shown to
significantly increase the risk of major hemorrhages and nearly double the risk of
intracranial hemorrhages as compared to antiplatelet therapy (14). In fact, annual

2

The international normalized ratio (INR) is a standardized score obtained from the prothrombin
time/international normalized ratio (PT/INR) test. The PT/INR test measures the effectiveness of warfarin
by assessing the time taken for blood to clot (9).
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incidences of about 0.6% for fatal bleeding, 3.0% for major bleeding, and 9.6% for minor
bleeding cases have been estimated among patients on warfarin (8). Thus, achieving the
drug’s therapeutic anticoagulation effect is challenging and associated with a high risk of
severe adverse events under standard warfarin therapy.
Warfarin-related adverse events are not only life threatening but they are also costly to
treat. In Ontario, AF-related hospitalizations due to bleeding are the costliest hospital
admissions, with an average cost of $22,051 (2010 CAD) per admission (2). Moreover,
the need for routine INR monitoring with standard warfarin care incurs a substantial
financial burden; about one third of direct medical costs incurred by AF patients can be
attributed to anticoagulation management (16).

1.3.2 Pharmacogenomics (PGx) based warfarin care
The observed wide interpatient variability in warfarin dose requirements has been
reported to depend on several demographic, clinical and pharmacogenetic factors.
Specifically, about 30% of this variability can be attributed to single nucleotide
polymorphisms (SNPs) in three pharmacogenes encoding the following enzymes
involved in warfarin metabolism and response: (i) cytochrome P450 (CYP) 2C9 involved
in S-warfarin metabolism (gene CYP2C9), (ii) vitamin K epoxide reductase (gene
VKORC1), the pharmacological target, and (iii) CYP4F2 (gene CYP4F2) involved in
vitamin K metabolism (17). Common SNPs in CYP2C9 cause impaired metabolism and
thus reduced drug clearance leading to increased drug levels in blood. Common SNPs in
VKORC1 lead to increased sensitivity to the anticoagulation effect of warfarin. As such, a
SNP in one or more of these pharmacogenes often results in lower dose requirement and
higher risk of over-anticoagulation. In fact, the administration of a standard warfarin dose
can result in severe bleeding complications in patients that are carriers of such SNPs in
these pharmacogenes because of reduced drug clearance and/or increased warfarin
sensitivity. Moreover, the prevalence of these SNPs can be high in certain populations.
For example, about 41% of Caucasians are carriers of CYP2C9 polymorphism, and thus,
require a lower than standard warfarin dosage to reach the drug’s therapeutic effect (18).
Similarly, about 37% of Caucasians and 14% of Africans carry a SNP of the VKORC1
gene, and thus, require a lower than standard warfarin dose to reach therapeutic INR.
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Moreover, the frequency of the CYP4F2 allele is about 30% among Caucasians and
Asians, compared to 7% in African Americans. As such, the US Food and Drug
Administration has revised warfarin dose recommendations to incorporate patient
genotype information (17). The incorporation of patient genotype information during the
initial warfarin dosing period has the potential to optimize warfarin use, to reduce risks of
life-threatening adverse events and to decrease the financial burden of warfarin-related
hospitalizations.
Pharmacogenomics (PGx) based warfarin therapy tailors the drug dose for each patient
using his/her genotypic information in conjunction with demographic and clinical
characteristics. Several genotype-guided warfarin dosing algorithms have been
developed. An algorithm developed by Gage et al. (2008) has been widely used for
warfarin dosing (19). This algorithm uses information on the CYP2C9 and VKORC1
genes, age, body surface area, amiodarone use, target INR, race and smoking status to
determine warfarin dose for each patient. In 2009, the International Warfarin
Pharmacogenetics Consortium reported another warfarin dosing algorithm (20). It was
based on a diverse population and explained about 47% of the interpatient warfarin dose
variation through genetic, clinical and demographic factors such as CYP2C9, VKORC1,
age, height, weight, amiodarone use, race and number of CYP enzyme inducers (20). In
addition, modified versions of these two and other dosing algorithms have been applied
in different clinical settings to successfully predict the correct warfarin dose for patients
before initiating treatment. For example, a prospective cohort study of outpatients
conducted at the London Health Sciences Center (LHSC) and the Ottawa Hospital
developed a novel pharmacogenetics-based treatment initiation protocol known as
WRAPID (Warfarin Regimen using A Pharmacogenetics-guided Initiation Dosing) that
predicts loading and maintenance doses based on genetics, clinical variables and patient
response during the first 9 days of initiating warfarin therapy. The model aimed to
provide a uniform response among all patients (21,22).
PGx-based warfarin care offers several benefits over standard warfarin care. PGx-based
warfarin dosing has increased the efficiency with which the therapeutic anticoagulation
effect is achieved among patients. Recent meta-analyses show that patients under PGx-
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based care reach the first stable therapeutic dose 5 days earlier and the maintenance dose
by about 10 days earlier compared to patients on standard warfarin therapy (23,24).
Moreover, PGx-based warfarin dosing has been shown to decrease the risk of adverse
events and associated hospitalizations during the initial dose adjustment period. In recent
meta-analyses, the risk of major hemorrhage has been significantly reduced by 30-60%
for patients who received PGx-based warfarin dosing as compared to patients who
received standard warfarin dosing (23,24). No significant reduction in the risk of
thromboembolism and all-cause mortality has been demonstrated by PGx-based warfarin
dosing when compared to standard warfarin dosing (23,24). However, a prospective
study that compared 896 patients receiving genotype-guided warfarin dosing with a
matched historical control of 2688 patients in the US found that PGx-based warfarin care
reduced all-cause hospitalizations by 31% and bleeding or thromboembolism-related
hospitalizations by 28% when compared to standard warfarin care (25).
The increased safety associated with PGx-based warfarin dosing may translate into
reduced financial burden posed by warfarin-related hemorrhagic hospitalizations.
However, PGx-based warfarin care also entails an upfront cost of the genotyping test. In
published cost-effectiveness analyses (CEAs), a genotyping test has been estimated to
cost anywhere between $500 and $800 USD per patient in the US and Canada (studies
range from 2009-2014) (10). In contrast, a more recent European CEA by Verhoef et al.
(2016) reported a point-of-care genotyping test costing (in 2014 cost year) £35.03 (~$70
2017 CAD) or 440 SEK (~$68 2017 CAD) in the UK and Sweden, as estimated from the
EU-PACT trial (26). At these genotyping test costs, PGx-based warfarin care was costeffective compared to standard warfarin care in the UK, Sweden and some US studies. In
contrast, Nshimyumukiza et al. (2013) found PGx-based warfarin care was not costeffective compared to standard warfarin care at a genotyping test cost of $615 (2010
CAD) per patient in Canada (27). The per patient cost of a genotyping test for four SNPs
in CYP2C9 (rs1799853, rs1057910) VKORC1 (rs9923231) and CYP4F2 (rs2108622),
was estimated to be less than $100 (2017 CAD) at the Personalized Medicine Clinic at
LHSC in Ontario, Canada (unpublished data). Thus, in Canada, it is important to assess if
the upfront cost of genotyping test outweighs the differences in lifetime costs between
PGx-based and standard warfarin care.
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1.3.3 Direct Oral Anticoagulants (DOACs): Apixaban and
Rivaroxaban
Given the challenges associated with warfarin therapy, a new class of drugs called
DOACs have been recently developed, including dabigatran, rivaroxaban and apixaban.
Here we will focus on the two most frequently prescribed DOACs in Canada:
rivaroxaban and apixaban (28). Rivaroxaban was approved for funding by the Ontario
Ministry of Health and Long-Term Care (MOHLTC) for stroke prophylaxis among AF
patients in July 2012, followed by apixaban in August 2013 (28). Apixaban and
rivaroxaban offer several advantages over warfarin and exert their anticoagulation
activity through direct inhibition of blood clotting factor Xa (11). In doing so, they
prevent the conversion of prothrombin to thrombin and reversibly cease the coagulation
cascade. As such, the DOACs have a more predictable therapeutic effect based on plasma
concentrations, require no routine INR monitoring, and demonstrate lower potential for
adverse events compared to warfarin. Consequently, DOACs offer several benefits over
warfarin in terms of clinical utility.
In large clinical trials, the DOACs have demonstrated greater or similar efficacy in stroke
prevention, and reduction in the risk of hemorrhagic events when compared to warfarin.
In the ARISTOTLE trial (n=18,201), apixaban reduced the risk of stroke and systemic
embolism by 21%, the risk of bleeding by 31%, and mortality by 11% when compared to
warfarin (11). Similarly, rivaroxaban has been shown to be non-inferior to warfarin and
reduced the risk of a composite outcome of stroke or systemic embolism in AF patients
by 12% in the ROCKET-AF trial (n=14,264) (11). Moreover, patients on DOACs have
lower drug discontinuation rates due to adverse events as compared to warfarin. In
summary, DOACs have been associated with a lower risk of adverse events in large
clinical trials, and hence, serve as a safer alternative to standard warfarin care.
The unit cost of DOACs is more than 20 times the cost of warfarin (29). In 2012, the
Ontario Drug Benefit (ODB) formulary covered DOAC treatments for seniors (65+ years
old) diagnosed with AF (28,30). Consequently, MOHLTC incurs a significantly higher
drug cost from the administration of DOACs to seniors with AF. Therefore, it is
important to carefully assess the cost-effectiveness of anticoagulation therapy with
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DOACs such as apixaban and rivaroxaban when compared to warfarin therapy in
Canada.

1.4 Rationale
Standard warfarin care has several drawbacks and poses a substantial burden on patient
health and the Canadian healthcare system. At present, there are several alternatives to
standard warfarin care. First, PGx-based warfarin dosing has been shown to be a safer
alternative to conventional warfarin dosing by reducing the risk of hemorrhages (31).
However, there remains considerable heterogeneity in the cost-effectiveness of PGxbased warfarin care as compared to standard warfarin care in the published literature.
This heterogeneity, in part, depends on the institutional environment within which the
CEA was conducted because of differences in cost of drugs and genotyping tests (10).
With current advances in technology, genotyping test costs have significantly decreased
compared to those estimated in published literature. As a result, there is a need to conduct
an updated CEA of PGx-based warfarin care using the latest Canadian cost data. Another
alternative is treatment with apixaban and rivaroxaban, a new class of drugs called
DOACs. There is a consensus that DOACs entail improved clinical effectiveness and
safety for AF patients as compared to standard warfarin care (11). However, the unit drug
cost of DOACs is more than 20 times the unit drug cost of warfarin (29). The ODB
formulary covered rivaroxaban and apixaban in 2012 for seniors (aged 65+) with AF in
Ontario requiring anticoagulation therapy (28). Thus, there is a need to conduct a CEA of
apixaban and rivaroxaban to understand whether the clinical advantages of DOACs
justify their higher drug costs in the Canadian health care setting.

1.5 Research Question
The purpose of this study is to conduct a CEA of pharmacogenomics (PGx) based
warfarin, apixaban and rivaroxaban care as compared to standard warfarin therapy among
newly diagnosed atrial fibrillation (AF) patients aged 65 years and older. The CEA will
estimate the incremental cost-effectiveness ratio (ICER) values of the three proposed
alternative treatments as compared to standard warfarin therapy using Canadian costs,
adverse event rates from the most recent clinical literature and meta-analyses and health
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utilities to understand the cost-effectiveness of anticoagulation strategies for AF patients
in Canada.
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Chapter 2
Literature review of cost-effectiveness analyses
Several cost-effectiveness analyses (CEAs) that compare standard warfarin therapy,
pharmacogenomics (PGx) based warfarin therapy, apixaban and rivaroxaban have been
conducted. Herein, a literature review of the relevant published CEAs is presented.

2.1 Cost-effectiveness analyses of PGx-based warfarin
care with standard warfarin care
To date, published CEAs of PGx-based warfarin therapy as compared to standard
warfarin therapy have produced conflicting results. In a recent systematic review of 12
CEA and cost-saving studies, three studies found PGx-guided warfarin therapy to be
cost-effective, four were inconclusive, and five found that PGx-based warfarin therapy
was not cost-effective at the country-specific willingness-to-pay (WTP) thresholds (1).
More specifically, PGx-based warfarin therapy has been favoured over standard warfarin
care in United Kingdom (UK) and Sweden (2). In Canada and the US, the clinical utility
of PGx-based warfarin dosing was found to be very small and costs were higher when
compared to standard warfarin dosing (3,4). Consequently, there is considerable
variability in the cost-effectiveness of PGx-based warfarin therapy; the results seem to
vary by country and the institutional environment. Key CEA studies comparing the costeffectiveness of PGx-based warfarin care with standard care are described and gaps in the
published literature are presented below.
Nshimyumukiza et al. (2013) investigated the cost-effectiveness of PGx-guided warfarin
management and standard warfarin management for the prevention of stroke and
systemic thromboembolism from the Quebec healthcare system perspective (3). This
study compared direct medical care costs and quality-adjusted life-years (QALYs)
incurred by a cohort of newly diagnosed atrial fibrillation (AF) patients aged 64 years and
older with no previous history of stroke over the 5-year time horizon. The Markov model
used INR specific risks of major hemorrhage (classified as intracranial and
gastrointestinal hemorrhages) and major thromboembolism (a composite outcome of
stroke, myocardial infarction, deep vein thrombosis and pulmonary embolism) using data
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derived from a US-based randomized clinical trial (RCT) (3). Nshimyumukiza et al.
(2013) found that genotype-guided warfarin management increased QALYs by 0.0085
units and costs by $460 (2010 CAD) as compared to standard warfarin therapy. This
resulted in an incremental cost-effectiveness ratio (ICER) of ~$55,000/QALY, which was
slightly above the willingness-to-pay (WTP) threshold of $50,000/QALY gained the
authors had assumed in the study. 3 The base case results were robust to deterministic and
probabilistic sensitivity analysis. According to the probability sensitivity analysis, there
was ~10% chance of PGx-based warfarin care being cost-effective at the WTP threshold
of $50,000/QALY.
Similarly, Patrick et al. (2009) found that PGx-based warfarin management was not costeffective as compared to standard warfarin management from a US societal perspective
(4). The CEA compared costs and QALYs incurred by a cohort of 70-year old newly
diagnosed AF patients over the lifetime horizon. The Markov model used INR-specific
risks of major hemorrhage (intracranial and extracranial) and ischemic stroke. The study
concluded that genotyping could be cost-effective under an assumed WTP of
$50,000/QALY if the time in therapeutic INR range was increased by more than 8.5%.
Finally, the probabilistic sensitivity analysis showed that genotype-guided warfarin
therapy was cost-effective ~42% of the time under this WTP threshold.
Although both Nshimyumukiza et al. (2013) and Patrick et al. (2009) found that PGxbased warfarin therapy was not cost-effective as compared to standard warfarin care in
Canada and the US, respectively, there are several limitations concerning study
conclusions. Firstly, Nshimyumukiza et al. (2013) and Patrick et al. (2009) modelled
major hemorrhage events (further classified as intracranial and extracranial
hemorrhages), but the authors excluded clinically relevant non-major (CRNM) bleeding
events. In fact, there has been little attempt to capture differences in costs and risks of
CRNMB events in much of the published CEAs to date. However, there is evidence that

3

A willingness-to-pay (WTP) is an estimate of how much a decision maker is willing to pay to obtain a
unit of health benefit (3).
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PGx-based warfarin dosing reduces the risk of CRNMB events as compared to standard
warfarin dosing (5). Moreover, CRNMB events are more common among warfarin users
than initially understood; they increase short-term costs and decrease patients’ quality of
life (6). As such, existing CEAs do not capture the health benefit and cost differences
between PGx-based and standard warfarin care.
Secondly, by modelling the distribution of INR ranges and INR-specific risks using a
single clinical trial population, generalizability of the results was limited. For example,
Nshimyumukiza et al. (2013) modelled the INR range distributions found in a cohort of
206 AF patients in the US because the INR data were not available on a Canadian
population cohort (3). This approach is a limitation because data obtained from one RCT
on a small sample size is less generalizable than evidence obtained from a systematic
review and meta-analysis. The allele frequencies of variants determining warfarin dose
requirement vary in different populations (7). As such, the use of evidence from a single
RCT introduces a certain degree of uncertainty into the generalizability of the
conclusions.
Finally, modelling INR-specific risks of adverse events applies an intermediate marker
for hard endpoints such as major hemorrhages. There is evidence that improved time in
therapeutic INR translates into decreased incidences of adverse events. However, not
every INR above (supratherapeutic) or below (subtherapeutic) the therapeutic range of 2
to 3 will result in an adverse event. Moreover, health states must be mutually exclusive,
but the transient nature of changing INR values applies strong assumptions among
existing models. As such, there is a gap in published CEAs on evaluating the costeffectiveness of PGx-based warfarin by modelling clinically relevant and hard outcomes.
Importantly, the cost-effectiveness of PGx-based warfarin therapy varies by country. For
example, Patrick et al. (2009) and Nshimyumukiza et al. (2013) did not find PGx-based
warfarin care to be cost-effective in the US and Canada. In contrast, Verhoef et al. (2016)
found that PGx-based warfarin care was cost-effective as compared to standard warfarin
care in the context of UK and Sweden (2). Verhoef et al. (2016) compared direct medical
care costs and QALYs incurred by a cohort of AF patients aged on average 70.9 years in

18

the UK and 72.5 years in Sweden, from the healthcare payer perspective over the lifetime
horizon. The Markov model modelled INR-specific risks of intracranial hemorrhage,
extracranial hemorrhage, ischemic stroke and transient ischemic attacks (TIA) using the
European Pharmacogenetics of Anticoagulant (EU-PACT) trial. The base case results
showed that the lifetime costs (in 2014 cost year) increased by £26 in the UK and by 382
Swedish krona (SEK) in Sweden under PGx-guided warfarin care. The incremental
QALYs were 0.0039 in the UK and 0.0015 in Sweden under PGx-guided warfarin. This
resulted in an ICER of £6,702/QALY gained in the UK and 253,848 SEK/QALY gained
in Sweden. Both ICER values were under the WTP of £20,000/QALY in the UK and
500,000 SEK/QALY in Sweden. The probabilistic sensitivity analysis showed that the
PGx-guided warfarin therapy was cost-effective 93% of the times in the UK and 67% of
the times in Sweden at these WTP thresholds. Verhoef et al. (2016) concluded that
pharmacogenetic-guided dosing of warfarin is a cost-effective strategy as compared to
standard warfarin dosing for AF patients in the UK and Sweden.
The observed heterogeneity among published CEAs by country indicate that regionspecific cost parameters should be incorporated in future CEA studies. To date,
Nshimyumukiza et al. (2013) is the only CEA study that compared PGx-based and
standard warfarin care in the context of Canada (3). In this study, the authors obtained
event-specific and ongoing unit costs from the Quebec health administrative data and the
published literature. The unit costs were multiplied by the estimated healthcare resource
use to estimate costs of genotype test, hemorrhagic and thromboembolic events and
follow-up costs for long-term sequalae of adverse events. Although this costing
methodology is sound in nature and the assumptions for estimated healthcare resource
use are justifiable, there is a gap in the published literature to model costs pertaining to
real-life consumption of healthcare resources in Canada.
In another CEA, Chong et al. (2014) assessed the cost-effectiveness of pharmacogeneticguided warfarin for a hypothetical cohort of 45 years and older patients initiating
warfarin therapy in Thailand (8). The CEA was conducted from both societal and health
care system perspective over the lifetime horizon. The CEA constructed a two-part
model; first, the patients were stratified by CYP2C9 and VKORC1 variants in a decision
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tree; then, patients transitioned through a Markov model illustrating the consequences of
two predominant warfarin-related adverse events (major bleeding and
thromboembolism). The base case results showed that the incremental cost was 2,959
Thai baht (2013 costing year) and 2,953 THB from the healthcare system and societal
perspective, respectively. PGx-based care increased QALYs by 0.002 units under both
healthcare system and societal perspective. This resulted in ICERs of 1,477,042 THB per
QALY gained and 1,473,851 THB per QALY gained under healthcare system and
societal perspective, respectively. Both ICERs were above the WTP of 160,000 THB and
the probabilistic sensitivity analysis showed that PGx-based care was cost-effective 4142% of the time. Moreover, deterministic sensitivity analysis showed that results were
most sensitive to the risk ratio (RR) of major bleeding among the VKORC1 variants. As
such, the authors concluded that PGx-guided warfarin was unlikely to be cost-effective in
Thailand.
Patrick et al. (2009), Nshimyumukiza et al. (2013) and Verhoef et al. (2016) modelled
INR-specific risks of adverse events, while Chong et al. (2014) modelled allele
frequencies of warfarin pharmacogenes and variant-specific risks of adverse events for
the Thai population. Both methodologies have made assumptions by connecting
intermediate outcomes such as INR ranges or allele frequencies with clinical outcomes
such as major hemorrhage and ischemic stroke.
In summary, PGx-based warfarin therapy has been shown to be cost-effective in the UK
and Sweden. In contrast, PGx-based warfarin care was not found to be cost-effective in
Canada, US and Thailand. Thus, there is potential for further CEA research using data on
adverse events and updated Canadian costs.

2.2 Cost-effectiveness analyses of apixaban and
rivaroxaban
To date, several cost-effectiveness analyses comparing the direct oral anticoagulants
(DOACs), such as apixaban and rivaroxaban, with standard warfarin care have been
conducted. In general, studies conducted in the context of Canada, US, France and UK
have found the DOACs to be cost-effective as compared to standard warfarin therapy. In
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most of these studies, apixaban has been the recommended anticoagulation strategy in
terms of cost-effectiveness. Moreover, rivaroxaban is usually ruled out by apixaban
through the principle of strong dominance or extended dominance. In contrast, these
DOACs were not cost-effective as compared to standard warfarin care in the context of
Germany, Thailand and China. Key CEA studies on the cost-effectiveness of apixaban
and rivaroxaban are described below and potential gaps in the published literature will be
mentioned (see Table 2.2.1 for additional details).
To date, Coyle et al. (2013) is the only Canadian study that assessed the costeffectiveness of DOACs, including apixaban, rivaroxaban and dabigatran, as compared to
standard warfarin care in preventing stroke and other cardiovascular events (9). This
CEA compared direct medical costs and QALYs incurred by a cohort of 72-year-old
Canadians on average with nonvalvular AF from the Ministry of Health perspective over
the lifetime horizon. The Markov model captured health states such as ischemic stroke,
major hemorrhage, intracranial hemorrhage, minor bleeding, transient ischemic attack,
myocardial infarction and pulmonary embolism. As compared to warfarin, apixaban,
rivaroxaban and dabigatran (150 mg) increased costs by $3,346, $3,396 and $2,866 (2011
CAD) and QALYs by 0.137, 0.061 and 0.137, respectively. This resulted in estimated
ICERs of $24,312/QALY, $55,757/QALY and $20,797/QALY gained for apixaban,
rivaroxaban and dabigatran (150 mg), respectively. Thus, dabigatran (150 mg) dominated
apixaban and rivaroxaban. However, as compared to warfarin alone, apixaban was found
to be cost-effective and the ICER for rivaroxaban was slightly above the WTP of
$50,000/QALY. The deterministic sensitivity analysis showed that estimated ICERs were
sensitive to drug costs, time horizon and treatment discontinuation rates. Moreover, the
probabilistic sensitivity analysis showed that apixaban, rivaroxaban and dabigatran were
cost-effective in 44.1%, 2.1% and 50.8% of the simulations, respectively, at the
$50,000/QALY WTP threshold. Coyle et al. (2013) concluded that dabigatran was the
optimal anticoagulation treatment strategy but also showed that apixaban was costeffective for AF patients in Canada.
At the time of the Coyle et al. (2013) study, the DOAC drug costs were not available
from the Canadian public healthcare perspective. Thus, the US drug costs were applied to
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the model and the drug cost for apixaban was assumed to be the same as dabigatran.
Currently, all the DOACs are included in the Ontario Drug Benefit (ODB) formulary and
the drug costs for DOACs are available from the Canadian public healthcare perspective.
In 2012, dabigatran was the first DOAC to be covered by the ODB formulary, followed
by apixaban and rivaroxaban shortly after (10). The inclusion of DOACs under the ODB
formulary led to rapid changes in the physician prescribing behaviour. When dabigatran
was first included in the formulary, there was a rapid increase in the total percent of
dabigatran prescriptions among all oral anticoagulant prescriptions for AF patients.
However, when rivaroxaban and apixaban were included in the formulary, there was a
simultaneous decrease in the percent of dabigatran prescriptions and increase in the
percent of apixaban and rivaroxaban prescriptions. A closer look at the clinical
effectiveness of dabigatran revealed that the drug fared worse in terms of drug safety as
compared to warfarin (11). Specifically, there has been a significant increase in the risk
of gastrointestinal bleeding associated with high-dose dabigatran use as compared to
warfarin, and a non-significant increase in the risk of myocardial infarction. Moreover,
dyspepsia (indigestion) is a common adverse event exclusive to dabigatran use.
Interestingly, physicians seemed to prefer prescribing apixaban and rivaroxaban over
dabigatran for AF patients in Ontario (10). This directly contradicts the results of Coyle
et al. (2013) who found that dabigatran was economically the optimal anticoagulation
strategy in Canada. Thus, an updated cost-effectiveness evaluation of apixaban and
rivaroxaban as compared to standard warfarin care is necessary from a Canadian
healthcare payer perspective.
A more recent study by López-López et al. (2017) assessed the cost-effectiveness of oral
anticoagulants, including apixaban, rivaroxaban and dabigatran, for the prevention of
stroke in the UK (12). The CEA compared direct medical care costs and QALYs incurred
by a cohort of 70-year old AF patients from the perspective of UK National Health
Services (NHS) over the lifetime horizon. The Markov model simulated patients through
health outcomes such as all ischemic stroke, systemic embolism, clinically relevant
bleeding (including major hemorrhage, intracranial hemorrhage and minor bleeding) and
myocardial infarction. As compared to warfarin, apixaban had the highest expected
incremental net benefit of £7,533, followed by dabigatran with an expected incremental
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net benefit of £6,365 and rivaroxaban with an expected incremental net benefit of £5,279
(cost year was not specified in source). The probabilistic sensitivity analysis showed that
the probability of apixaban, dabigatran and rivaroxaban was cost-effective was close to
60%, 25% and 10% at a WTP threshold of £20,000/QALY.
Overall, apixaban has been found to be the recommended anticoagulation strategy with a
high degree of certainty in various countries including the US, Taiwan, Italy, France,
Portugal, Slovenia, Belgium, and Singapore (13–21) (Table 2.2.1). Among DOACs,
apixaban produces the highest incremental health benefit at the lowest incremental cost.
However, some studies found that the DOACs are not cost-effective in the context of
Thailand, Germany and the US. For example, a CEA by Jarungsuccess et al. (2014)
recommended dose-adjusted warfarin therapy for 65-year old AF patients in Thailand and
found that DOACs could be cost-effective if the drug unit cost decreased by 85% (22).
Similarly, Dilokthornsakul et al. (2019) found that DOACs were not cost-effective at the
WTP of 160,000 THB/QALY for the Thai AF population and these results were sensitive
to DOAC drug costs among other clinical factors (23). A CEA by Krejczy et al. (2014)
also did not find the DOACs to be cost-effective at the current drug unit cost in the
prevention of stroke among AF patients in Germany (24). Thus, the cost-effectiveness of
DOACs seems to be very sensitive to drug costs, which varies by geographical region.
Given the influence of drug costs and the shortcomings of the previous Canadian CEA
study, there is the potential need for further research and evaluation of the costeffectiveness of DOACs using updated Canadian cost data.
Although the cost-effectiveness of DOACs were sensitive to drug cost in the context of
Thailand and Germany, You et al. (2013) found that the DOACs had the potential to be
cost-effective in the US if the time in therapeutic range (TTR) under standard warfarin
care was below 60% (25). In addition to drug costs, the authors found that the costeffectiveness of DOACs was sensitive to quality of anticoagulation control with warfarin
use and anticoagulation service cost in the US. PGx-based warfarin care optimizes
warfarin dosing and TTR. However, You et al. (2013) did not include PGx-based
warfarin care as an alternative OAC strategy in their CEA. This highlights a gap in the
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published literature on the cost-effectiveness analysis of standard warfarin care, PGxbased warfarin care and DOACs for AF patients in a single study.
In summary, the DOACs have been consistently shown to be or have the potential to be
cost-effective alternatives to standard warfarin care. Among apixaban and rivaroxaban,
apixaban is often the recommended treatment when compared to standard warfarin care.
However, it has been shown that the cost-effectiveness of DOACs is influenced by drug
costs and anticoagulation control under warfarin care. The unit costs of DOACs vary by
geographical region which highlights potential for research in Canada. Moreover, PGxbased warfarin care has been shown to improve the anticoagulation control of warfarin
use. However, there are a limited number of studies that evaluate the cost-effectiveness of
all four strategies; standard warfarin care, PGx-based warfarin care, apixaban and
rivaroxaban, as described in the next section.

2.3 Cost-effectiveness analyses of PGx-based warfarin
care, apixaban and rivaroxaban relative to standard
warfarin care
A few published CEAs in the literature compared PGx-based warfarin care, standard
warfarin care, apixaban and rivaroxaban for AF patients.
You et al. (2013) assessed the cost-effectiveness of pharmacogenetic-guided selection of
warfarin and DOACs, including apixaban and rivaroxaban, as compared to standard
warfarin for stroke prevention (26). The CEA compared direct medical costs and QALYs
incurred by a cohort of 65-year-old newly diagnosed AF patients from the US public
healthcare payer perspective using two treatment strategies. In the first strategy, all
patients undergo standard warfarin care. In the second strategy, patients are genotyped for
CYP2C9 and VKORC1 genes and then, wild-type patients are triaged into genotypeguided warfarin care and variant carriers are administered DOAC treatment. The Markov
model captured the following adverse events: ischemic stroke, major hemorrhage (ICH
and ECH) and myocardial infarction. The base-case analysis showed that
pharmacogenetics-guided selection of warfarin increased QALYs by 0.191 units and
costs by $543 (2013 USD). The pharmacogenetics-guided selection of warfarin was

24

found to have an ICER of $2,843/QALY (2013 USD) gained. The deterministic
sensitivity analysis showed that the base case results were sensitive to the DOAC drug
costs, relative risk of stroke, relative risk of hemorrhage and the time spent in therapeutic
range under warfarin care. Moreover, the probabilistic sensitivity analysis showed that
the probability of PGx-guided warfarin being cost-effective was 96.4% at WTP threshold
of $50,000/QALY USD. Although this study modelled genotype-guided warfarin care,
their research question assessed the cost-effectiveness of pharmacogenetics use to select
between warfarin (included only patients lacking select CYP2C9 and VKORC1 variants)
and DOAC treatments. As such, there is still a gap in the published literature
necessitating evaluation of the comparative cost-effectiveness of treatment strategies for
AF patients receiving either standard warfarin dosing, PGx-guided warfarin dosing,
apixaban or rivaroxaban treatment in current clinical practice.
In another study, Pink et al. (2014) assessed the cost-effectiveness of DOACs,
pharmacogenetic-guided warfarin dosing and standard warfarin dosing in the UK (27).
The authors used a discrete-event simulation model to compare direct medical costs and
QALYs in AF patients (72.5-year-old on average) from the perspective of the UK public
healthcare payer over the lifetime horizon. In their CEA, Pink et al. (2014) conducted a
pharmacokinetic-pharmacodynamic simulation using clinical trials data to estimate the
distribution of INR ranges under standard and PGx-based warfarin dosing. Then, INRspecific risks of adverse events were modelled using an updated meta-analysis. The study
captured the following adverse events: stroke or systemic embolism, transient ischemic
attack, major hemorrhage (including intracranial hemorrhage) and myocardial infarction.
The base-case analysis showed that PGx-based warfarin care increased QALYs by 0.003
units and apixaban increased QALYs by 0.130 as compared to standard warfarin care.
The discounted lifetime costs in 2011 cost-year were £8,437, £5,921, and £5,880 for
apixaban, PGx-guided warfarin care and standard warfarin care, respectively. Both
apixaban and PGx-based warfarin care improved health outcomes at an additional cost
relative to standard warfarin care. The estimated ICER value was £13,226/QALY gained
for PGx-guided warfarin care as compared to standard warfarin care. In comparison, the
ICER was £19,858/QALY gained under apixaban treatment as compared to PGx-guided
warfarin care. As compared to standard warfarin care, rivaroxaban increased QALYs and

25

costs. However, rivaroxaban was dominated by apixaban because it resulted in lower
QALYs but higher costs. The probabilistic sensitivity analysis showed that PGx-guided
warfarin had a high probability of being cost-effective as compared to standard warfarin
care at the WTP threshold of £6,700/QALY and apixaban had a high probability of being
cost-effective at the WTP threshold of £20,500/QALY when compared to PGx-guided
warfarin. In summary, apixaban resulted in the largest gains in QALYs and had the
highest probability of being cost-effective among all four strategies.
In another CEA, Janzic and Kos (2015) assessed the cost-effectiveness of DOACs,
including apixaban and rivaroxaban, and PGx-based warfarin as compared to standard
warfarin care for stroke prevention in a Markov cohort analysis (17). The CEA compared
direct medical costs and QALYs in a cohort of 70-year-old AF patients from the
Slovenian healthcare payer perspective over the lifetime horizon. All patients began from
the event-free health state and could experience the following adverse events at monthly
intervals: ischemic stroke (disabling, non-disabling or fatal), intracranial hemorrhage
(disabling, non-disabling or fatal); extracranial hemorrhage (fatal or non-fatal),
systematic embolism (no change in state); myocardial infarction (no change in state or
death) and non-event death. The modelled health states comprised of well, non-disabled
and on-treatment, disabled and on-treatment, disabled and off-treatment, and nondisabled
and off-treatment. The authors modelled distribution of TTR using the RE-LY,
ROCKET-AF, ARISTOTLE and ENGAGE AF-TIMI trials and predicted hemorrhagic
and thromboembolic rates as a function of TTR under standard warfarin care. The EUPACT trial reported that PGx-based warfarin dosing increased the TTR by 8.8% in the
first 4 weeks and then, by 10.2% in the subsequent 4 weeks. Janzic and Kos (2015) used
this finding to model improved quality of warfarin anticoagulation control under PGxbased warfarin care for the first 6 months of treatment initiation. The base case analysis
showed that, as compared to standard warfarin care, the incremental costs in 2014 cost
year were about €16, €3,678 and €4,193 and the incremental QALYs were about 0.003,
0.235 and 0.064 for PGx-based warfarin care, apixaban and rivaroxaban, respectively.
Thus, the corresponding estimated ICERs were €6,959/QALY, €15,679/QALY and
€66,328/QALY. Apixaban was found to be a cost-effective alternative to standard
warfarin care with a high degree of certainty at the WTP threshold of €20,000/QALY and
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dominated rivaroxaban. Although PGx-based warfarin was found to be cost-effective, the
absolute incremental benefit was small. Thus, the authors did not recommend PGx-based
warfarin care as a “structural measure” to improve long-term anticoagulation control.
Although both Pink et al. (2014) and Janzic and Kos (2015) provide valuable insights
about the comparative cost-effectiveness of PGx-based warfarin care, apixaban and
rivaroxaban, to date, no Canadian study has compared all four treatment strategies.
In summary, published CEAs comparing standard warfarin care, PGx-based warfarin,
apixaban and rivaroxaban show that the DOACs and PGx-based warfarin therapy can be
cost-effective strategies as compared to standard warfarin care. Moreover, apixaban is
usually the recommended DOAC for AF patients. However, there is heterogeneity in the
published literature and the results vary by population and geographical region. The
estimated ICER values are sensitive to the DOAC drug costs and efficacy of
anticoagulation managements under warfarin care. In addition, most of the published
CEAs have overlooked to model the cost and risk differences associated with clinically
relevant non-major bleeding events. Considering the emerging evidence that highlights
the clinical importance of CRNMB events and latest meta-analyses that show a
significant reduction in adverse events under alternative to warfarin treatments, there is
potential for further research using latest effectiveness data and region-specific costs in
the context of Canada.
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Table 2.2.1: Summary of published cost-effectiveness analyses of DOACs, including apixaban and rivaroxaban, as compared to standard doseadjusted warfarin care included in the literature review.
First
Year
Author
(Reference)
Canestaro
2013
(14)

Setting

Target
population

Interventions

US

70-year-old
warfarin
eligible
patients

Dabigatran 150
mg BID,
Apixaban 5 mg
BID,
Rivaroxaban 20
mg QD

Coyle (9)

2013

Canada

72-year-old Dabigatran (150
AF patients mg twice daily
or 110 mg twice
daily)
Rivaroxaban
Apixaban
Aspirin in case
of therapy
discontinuation

Harrington
(28)

2013

US

70-year-old Apixaban (5 mg
AF patients BID)
Rivaroxaban
(20 mg QD)

Health Outcomes

Cycle
length

Time
frame

Perspective

Base Case Analysis
Results

Ischemic stroke, non– 1central nervous system month
embolism, intracranial cycle
hemorrhage,
gastrointestinal bleeds,
extracranial nongastrointestinal bleed,
myocardial infarctions
and death

Lifetime

Societal
perspective
(all costs
were
included
regardless
of payer)

Compared with warfarin,
dabigatran, rivaroxaban,
and apixaban cost
$140,557, $111,465, and
$93,062 per additional
QALY gained,
respectively, in 2011
USD. When rank-ordered
by costs, apixaban was
found to be optimal.

Ischemic stroke (fatal,
major or minor),
bleeding (fatal,
intracranial
hemorrhage, major
non-ICH, and minor),
TIA, myocardial
infarction, pulmonary
embolism (fatal or
nonfatal) and death
Ischemic stroke
(minor or major),
Intracranial
hemorrhage (minor or

3month
cycle

Lifetime

Third-party
payer
perspective
of the
provincial
ministry of
health

Dabigatran 150 mg was
the recommended option
and dominated all other
treatment options.

1month
cycle

30 years
or until
death

Societal

Apixaban was the
recommended strategy,
followed by dabigatran
and then rivaroxaban.

28

Dabigatran (150 major), myocardial
mg)
infarction (MI), and
death
You (25)

2013

US

65-year-old
newly
diagnosed
AF patients

DOACs
(dabigatran
150mg twice
daily,
rivaroxaban
20mg daily, or
apixaban 5mg
twice daily)

Ischemic stroke (mild,
moderate or severe),
major bleeding (intraor extracranial
hemorrhage),
myocardial infarction
and death

1month
cycle

25 years

Healthcare
payer

Jarungsuccess (22)

2014

Thailand

65-year-old
newly
diagnosed
AF patients

Dabigatran
(150mg BID or
110mg BID)
Rivaroxaban
20mg/day QD
Apixaban 5mg
BID

Ischemic stroke (nondisabling [mRS=0–1],
disabling [mRS=2–
5]), major bleeding
(non-disabling
[mRS=0–2], disabling
[mRS=3–5]),
intracranial
hemorrhage,
extracranial
hemorrhage,
myocardial infarction
(with/without

1-year
cycle

30 years
or until
death

Both
government
and societal
perspectives

DOACs increased
lifetime costs and
QALYs as compared to
standard warfarin care.
At the WTP threshold of
$50,000/QALY, the
DOACs were costeffective in ~80% of the
time at the TTR <= 60%
under warfarin therapy or
at a monthly drug cost of
$200 or less.
Warfarin was the
recommended option
from both healthcare and
societal perspective in
Thailand. The DOACs
had the potential to be
cost-effective if the drug
unit cost was reduced by
at least 85%.
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complications) and
death
Kongnakorn (18)

2014

Belgium

Krejczy
(24)

2014

Germany

Belgium
AF patients
eligible for
anticoagulation
treatment

Apixaban 5mg
twice daily,
Rivaroxaban
20mg once
daily,
Dabigatran
110mg twice
daily or 150mg
twice daily

Ischemic stroke,
hemorrhage (mild,
moderate, severe and
fatal), systemic
embolism, intracranial
hemorrhage, other
major bleeding,
clinically relevant
non-major bleeding
and myocardial
infarction
65-year-old Dabigatran (110 Ischemic stroke (fatal,
AF patients and 150mg
moderate to severe,
BID),
mild), hemorrhage
Rivaroxaban
(fatal, moderate to
20mg OD,
severe intracranial,
Apixaban 5mg
mild intracranial,
BID
major non-cerebral,
minor non-cerebral),
transient ischemic
attack, myocardial
infarction (MI),
recurrent and
combined events and
death

6-week
cycle

Lifetime

1-year
cycle

20 years

Belgian
healthcare
payer; the
Belgian
National
Institute for
Health and
Disability
Insurance
(RIZIV/INA
MI)
German
public
healthcare
insurance

Apixaban was found to
be a cost-effective
strategy as compared to
warfarin at an ICER of
€7,212/QALY gained
(2013 EUR). Apixaban
dominated rivaroxaban.

At the current drug
prices, the DOACs were
not found to be costeffective from the
German public health
care insurance
perspective.
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Lanitis (13)

2014

France

Rognoni
(29)

2014

Italy

Wisløff (15) 2014

Norway

French AF
patients

Apixaban (5 mg
BID)
Rivaroxaban
(20 mg QD)
Dabigatran (150
mg or 110 mg
BID)
Aspirin

Ischemic stroke (mild,
moderate, severe or
fatal), hemorrhage
(intracranial
hemorrhage, major
bleed or clinically
relevant nonmajor
bleeding), systemic
embolism, myocardial
infarction and death
71-year-old Apixaban (5 mg Ischemic stroke
AF patients BID)
(temporary, mild,
Rivaroxaban
moderate/severe or
(20 mg QD)
fatal), intracranial
Dabigatran (150 hemorrhage (mild,
mg or 110 mg
moderate–severe or
BID)
fatal), minor and
major extracranial
bleedings, myocardial
infarction and death
75-year-old Sequential
Ischemic stroke (IS),
general
Dabigatran
intracranial
Norwegian (2x150 mg),
hemorrhage, major
population Dabigatran
gastrointestinal
with
(2x110mg),
bleeding, acute
medium
Apixaban
myocardial infarction
risk of
(2x5mg),
and death
stroke
Rivaroxaban
(1x20mg)

6-week
cycle

lifetime

French
National
Health
Insurance
(healthcare
payer)

Apixaban was found to
be the economically
efficient alternative to
warfarin and dominated
all other treatment
alternatives in AF
patients eligible for
stroke prevention in
France.

3month
cycle

Lifetime

Italian
National
Health
System

Apixaban was the
recommended strategy at
the willingness-to-pay
(WTP) threshold of
€25,000/QALY gained
(2013 EU).

N/A

Lifetime

Norwegian
publicly
financed
healthcare
system

Sequential dabigatran
(2x150 mg before the age
of 80 and then, 2x110 mg
at the age of 80) was the
recommended alternative
for AF patients, followed
by apixaban. The costeffectiveness of
dabigatran was found to
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be dependent on the dose
switching age.
Zheng (30)

2014

UK

71-year-old Dabigatran
AF patients 150mg or
110mg based on
patient age,
Rivaroxaban,
Apixaban

Costa (16)

2015

Portugal

AF patients
with a
mean age
of 70 years
old

Shah (20)

2016

US

Apixaban 2.55mg twice
daily,
Dabigatran
(150mg up to
80yrs and
110mg after 80
years),
Rivaroxaban
15-20mg once a
day
AF patients Apixaban (5mg
with a
BID),
CHADS2
rivaroxaban
score of ≥1 (20mg QD),
Dabigatran
(150mg BID),

Primary and recurrent
IS, systemic
embolism, acute
myocardial infarction,
transient ischemic
attack, intracranial
hemorrhage, major
extracranial
hemorrhage, minor
bleeding and death
Ischemic stroke (mild,
moderate, severe and
fatal), bleeding
(intracranial, other
major bleeding and
clinically relevant
non-major bleeding),
myocardial infarction
and death

3month
cycle

Lifetime

UK payer
perspective

Dabigatran was found to
be economically
dominant over
rivaroxaban and apixaban
in the UK setting.

6-week
cycle

Lifetime

Portuguese
national
healthcare
system

Lifetime

Private
payer's
perspective

Apixaban provided the
most health gains at the
lowest incremental cost
and dominated
rivaroxaban. As such,
apixaban was found to be
the optimal alternative to
warfarin in AF patients
from the perspective of
the Portuguese national
healthcare system.
Apixaban was the
recommended strategy
over standard warfarin
care with an estimated
ICER of $25,816/QALY

Ischemic stroke
1(transient ischemic
month
attacks, reversible,
cycles
major, minor, or fatal),
intracranial
hemorrhage (major,
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Edoxaban
(60mg QD)

Zhao (21)

2016

Singapor
e

Hernandez
(19)

2017

US

65-year-old Apixaban 5mg
AF patients twice daily,
Rivaroxaban
20mg daily,
Aspirin low
dose (<100mg
daily), Aspirin
medium dose
(100-300mg
daily),
Aspirin/clopido
grel (75mg once
daily),
Dabigatran
110mg twice
daily or 150mg
twice daily,
Edoxaban 60mg
daily
65-year-old Apixaban 5 mg,
AF patients Rivaroxaban 20
mg, Dabigatran
150 mg or 110
mg, Edoxaban
60 mg

minor or fatal),
extracranial
hemorrhage (ECH)
and death
Ischemic stroke
1(minor, major or
month
fatal), intracranial
cycles
hemorrhage (minor,
major or fatal),
gastrointestinal
bleeding (non-fatal or
fatal), myocardial
infarction (non-fatal or
fatal) and non-event
death

Severe stroke, other
1-year
thromboembolic
cycles
events including minor
ischemic stroke,
transient ischemic
attack and systemic
embolism, intracranial

(2015 USD) and
dominated rivaroxaban.

Lifetime

Based on
the info
under cost
source, it
seems the
perspective
is that of a
healthcare
payer which
could be the
hospital or
the
public/gover
nment. The
payer is not
specified in
the article.

All the DOACs (except
dabigatran 110) were
found to be cost-effective
as compared to standard
warfarin care at the WTP
threshold of
$49,700/QALY (2015
USD). Apixaban
produced the highest
number of QALYs
(11.22) at the lowest
ICER value (2015 USD
24,476/QALY gained).

Until 90
years of
age or
death

US-based
third-party
payer

The DOACs increased
QALYs at a higher cost
as compared to standard
warfarin care. Among the
DOACs, apixaban was
the recommended
strategy at WTP
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bleeding, extracranial
bleeding and death

Liu (31)

2017

Taiwan

LópezLópez (12)

2017

UK

18+ year
old AF
patients
enrolled in
the national
health
insurance
program

Apixaban (5 mg
BID)
Rivaroxaban
(20 mg QD)
Dabigatran (150
mg or 110 mg
BID)

Ischemic stroke (mild,
moderate or severe),
hemorrhage (mild
ICH, moderate ICH,
severe ICH, major
bleeding, clinically
relevant non-major
bleeding), myocardial
infarction, systemic
embolism and death
70-year-old Antiplatelet
Ischemic stroke,
AF patients (aspirin, <159
intracranial
mg once daily;
hemorrhage, other>= 150 mg once clinically relevant
daily)
bleeding, transient
Apixaban (5 mg ischemic attack,
twice daily)
systemic embolism,
Rivaroxaban
myocardial infarction
(20 mg once
and death
daily)
Dabigatran (110
mg or 150 mg
twice daily)
Edoxaban (30

thresholds above
$84,129/QALY (2012
USD) and dominated
rivaroxaban.
6-week
cycle

Lifetime

Healthcare
payer

Apixaban was the
recommended OAC
alternative to standard
warfarin care.

3month
cycle

Lifetime

National
Health
Services
(NHS)

Apixaban (5 mg twice
daily) was the
recommended
anticoagulation strategy
at the WTP of
€20,000/QALY gained.
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Hospoda
(32)

2018

US

Dilokthornsakul (23)

2019

Thailand

mg and 60 mg
twice daily)
65-year-old Apixaban 5mg,
AF patients Edoxaban
60mg,
Rivarixaban
20mg,
Dabigatran
(150mg or
110mg)

68-year-old Apixaban 5 mg
AF patients twice daily,
Rivaroxaban 20
mg once
daily,
Dabigatran 150
mg or 110 mg
twice daily,
Edoxaban 60
mg and 30 mg
once daily

Ischemic stroke, other
thromboembolic
events (minor
ischemic stroke,
transient ischemic
attack or systemic
embolism),
intracranial bleeding,
extracranial bleeding
and death
Ischemic stroke,
extracranial
hemorrhage (fatal or
non-fatal), intracranial
hemorrhage (mild,
moderate, severe or
fatal), myocardial
infarction (fatal or
non-fatal) and death

1-year
cycles

until 90
years
old or
death

US thirdparty payer
perspective

Warfarin with a time in
therapeutic range (TTR)
of 70% or less was a
cost-effective strategy
and dominated apixaban
and rivaroxaban at the
WTP threshold of
$100,000/QALY USD.

1-year
cycles

Lifetime

Societal
perspective

In Thailand, all the
DOACs were not found
to be cost-effective for
the AF population. The
cost-effectiveness
acceptability curve
indicated that apixaban
had the potential to be a
cost-effective strategy at
higher WTP thresholds
as compared to other
DOACs.

Note: Target population is the average age used for the modelled analysis. BID; two times a day. QD: once daily
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Chapter 3
Cost-effectiveness analysis of pharmacogenomics (PGx)
based warfarin, apixaban and rivaroxaban compared to
standard warfarin for atrial fibrillation patients in Canada
3.1 Introduction
Atrial fibrillation (AF) is a common cardiac arrythmia among seniors (aged 65 years and
older) in Canada. The prevalence of AF is approximately 300,000 Canadians in Canada
(1). AF patients suffer from high morbidity and mortality risk, increasing the risk of
stroke 3-5 times and death by 3.5-fold as compared to the general population. In addition
to posing a substantial burden on patients’ health, AF entails a huge financial burden on
the Canadian healthcare system. In the fiscal year of 2007-2008, the estimated cost of
AF-related hospitalizations was $815 million (2010 CAD), representing some 4.6% of
acute inpatient costs. In addition, AF-related ischemic stroke or transient ischemic attack
complications were associated with the longest length of hospital stay of about 20.2 days
with an average cost of $19,113 (2010 CAD) per hospitalization (1).
Warfarin, a relatively inexpensive oral anticoagulant, has been the cornerstone of AF
therapy for decades to mitigate AF-related adverse events (2). Although warfarin has
been shown to reduce the risk of stroke by up to 60%, the drug’s optimal therapeutic
effect, defined by an international normalized ratio (INR) of 2-3 (also therapeutic range),
is difficult to achieve among patients due to highly variable dose requirements (3).4
Warfarin’s unpredictable pharmacological response is caused by interpatient genetic
variability in drug metabolism and response (4). In practice, the therapeutic dose for each
patient is typically determined by trial and error, an approach that often results in INRs
above or below the therapeutic range. Consequently, patients under standard warfarin
care require repetitive INR tests and frequent dose adjustments (3). Not only is this

4

The international normalized ratio (INR) is a standardized score obtained from the prothrombin
time/international normalized ratio (PT/INR) test, which measures the effectiveness of warfarin by
assessing the time it takes for blood to clot (10).
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inconvenient to patients, it also increases the risk of adverse events, particularly during
the initial dose adjustment period. Due to its narrow therapeutic window, subtherapeutic
warfarin doses can lead to stroke while supratherapeutic doses may cause hemorrhagic
events. Annual incidences of 0.6% fatal bleeding, 3.0% major bleeding and 9.6% minor
bleeding have been estimated for patients on warfarin therapy (3). As expected, these
adverse events entail substantial financial strain on Canadian hospitals. In Ontario,
bleeding complications are the costliest; AF-related hospitalizations cost an average of
$26,746 (2010 CAD) per hospital admission (1).
About 18%, 30%, and 11% of the interpatient variability in therapeutic dose in patients of
European ancestry can be attributed to common genetic polymorphisms in the Swarfarin-metabolizing enzyme cytochrome P450 (CYP) 2C9, the pharmacological target
of warfarin vitamin K epoxide reductase complex 1 (VKORC1), and vitamin K1
hydroxylase (CYP4F2), respectively (5). Pharmacogenomics (PGx)-based warfarin care
tailors drug dose for each patient using his or her genotype information in conjunction
with the relevant demographic and clinical variables such as age, sex, weight, height, and
smoking status. Two recent meta-analyses have shown that PGx-based warfarin dosing
increases the efficiency with which the therapeutic effect is achieved among patients
while decreasing the risk of adverse events during the initial dose adjustment period
(6,7). Thus, PGx-based warfarin care has the potential to optimize warfarin use and
decrease the financial burden entailed by warfarin-related adverse events. However, there
is an upfront cost of genotyping test incurred under PGx-based warfarin care.
Direct oral anticoagulants (DOACs) such as apixaban and rivaroxaban represent another
treatment alternative available recently for patients with AF, which has confirmed noninferiority to warfarin (8). DOACs have the added benefits, including more predictable
dosing requirements, rapid onset of drug action, fewer drug-food interactions, and no
need for routine monitoring (8). However, DOACs may not be suitable for patients with
poor renal function and have substantially higher drug costs than warfarin. Over the last
few years in Canada, there has been a shift in physician prescribing behaviour from
warfarin to DOACs, such as apixaban and rivaroxaban (9). Since the inclusion of DOACs
in the provincial formulary in 2012, apixaban and rivaroxaban represent a growing
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segment of oral anticoagulant (OAC) prescriptions with a simultaneous decline in
warfarin use. As DOAC treatments are adopted in current clinical practice, there is a need
for an updated cost-effectiveness analysis (CEA) of existing OAC therapies for AF
patients.
Existing CEAs have shown that the cost-effectiveness of OAC treatments is sensitive to
drug costs and quality of anticoagulation control under warfarin care, which varies by
geographical region and patient populations. In the context of Thailand, Germany and
United States, the DOACs can be cost-effective conditional on reduced drug acquisition
costs by almost 80% and time in therapeutic range (TTR) under warfarin care by almost
60% (10–12). In other studies, apixaban and PGx-based warfarin care have been found to
be cost-effective compared to standard warfarin care in the context of Slovenia and the
United Kingdom (13,14). As such, there is considerable between-study heterogeneity in
the published literature that, in part, depending on the institutional environment within
which the CEA was conducted. Thus, previous CEAs may not inform optimal AF
treatment strategy in Canada from the resource allocation perspective.
In previous Canadian CEAs, dabigatran was found to be the most cost-effective strategy
(15,16). However, latest clinical evidence shows that high dose dabigatran is associated
with higher gastrointestinal bleeding than standard warfarin care. Moreover, dyspepsia
(indigestion) is a common adverse event of dabigatran use and discourages prescription
(4). Although dabigatran was the first DOAC to be publicly funded in Canada, apixaban
and rivaroxaban were included in the Ontario Drug Benefit (ODB) formulary shortly
after (9). Since then, there has been a simultaneous decrease in the percentage of
dabigatran prescriptions and increase in the percentage of other DOAC prescriptions (9).
Contrary to previous CEA recommendation, physicians in Canada prefer prescribing
apixaban or rivaroxaban over dabigatran. Moreover, the evidence used to populate
previous CEA models was limited. Most of the previous studies have not captured costs
and risk differences associated with clinically relevant non-major bleeding. Considering
the emerging evidence on the clinical effectiveness and safety of DOACs and
heterogeneity in existing studies, there is a need for a comprehensive CEA using latest
effectiveness data and region-specific updated costs in the context of Canada.
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Since the current healthcare climate in Canada requires efficient allocation of resources,
an updated CEA is critical for all stakeholders given the inclusion of DOACs in the ODB
formulary and the changing treatment landscape in long-term OAC therapies for AF
patients. Accordingly, we assessed the cost-effectiveness of PGx-based warfarin,
apixaban and rivaroxaban as compared to standard warfarin care for AF patients in
Canada using updated clinical evidence on effectiveness and costs.

3.2 Methods
3.2.1

Overview

We developed a Markov model to assess the cost-effectiveness of PGx-based warfarin,
apixaban and rivaroxaban compared to standard warfarin care. The model was populated
with parameters obtained from published literature and some costs obtained from the
ICES (formerly known as the Institute of Clinical and Evaluative Sciences) and the
London Health Sciences Centre (LHSC).
Cost effectiveness was evaluated using the incremental effectiveness ratio (ICER).
Benefits were measured in discounted life-time quality-adjusted life-years (QALYs) and
life-years (LYs) gained and the number of each type of acute event. QALYs were
calculated by adjusting life years of survival by a health state utility value, which ranges
from 0 to 1, with 0 representing death and 1 representing perfect health. The CEA
adopted the Canadian public healthcare perspective and captured all direct medical care
costs from the Ontario population, whenever available. When estimating literature-based
model parameters, Canadian studies were prioritized. In case of limited Canadian data,
US and European studies were selected. Deterministic and probabilistic sensitivity
analyses were carried out to characterize uncertainty introduced by model parameters.
The target population was Canadian senior residents with an average age of 65 years or
older who were diagnosed with nonvalvular AF and initiated long-term anticoagulation
therapy for the first time. In the base case analysis, we considered a population with no
history of stroke, myocardial infarction, or other cerebrovascular or cardiovascular event.
In sensitivity analysis, we varied the characteristics of patients.
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The following treatment strategies were compared: standard warfarin care, PGx-based
warfarin care, apixaban, and rivaroxaban, with standard warfarin care as the reference
treatment. It was assumed that all patients under PGx-based warfarin care were
genotyped before initiating therapy, which is predicted to reduce the short-term risk of
warfarin-related complications. We restricted our analysis to apixaban and rivaroxaban;
dabigatran was excluded because of concerns about its safety and limited uptake in
current clinical practice.
The expected costs, QALYs and LYs under each treatment strategy were compared over
the lifetime horizon. The patients transitioned between health states at monthly intervals
to adequately capture risk and cost differences between treatment strategies. PGx-based
warfarin care has been shown to improve the TTR by about 6% as compared to standard
warfarin (59.4% vs 53%; Mean Difference = 6.35 [95% Cl, 1.76 to 10.95]; P =0.007; I2
=73%) (6). However, the benefits of PGx-based warfarin therapy are more evident after
one month because the higher percent TTR translates into lower risks of major
hemorrhage at more than 1 month of follow-up. As such, a monthly cycle length was
considered appropriate for this CEA. Costs, QALYs and LYs were discounted at an
annual rate of 1.5% as per the Canadian Agency for Drug and Technologies in Health
(CADTH) guidelines (17).
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3.2.2

Markov model

A.

B.

Figure 3.2.6.1: A, Markov model showing health states in order of severity. B, Tree
diagram (T) showing adverse events in each health state. All patients begin from the
“Healthy with AF” health state.
Hx, history; PGx, pharmacogenomics; ICH, intracranial hemorrhage; IS, ischemic stroke;
TIA, transient ischemic attack; SEE, systemic embolic events
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A decision-analytic Markov model was developed in TreeAge Pro (2020). The Markov
model structure was based on recommendations from the Canadian stroke best practice
guidelines, other peer-reviewed medical literature, and expert opinion (18–20). The
Markov model consisted of the following health states (Figure 3.2.6.1): healthy-with-AF,
history of intracranial hemorrhage (ICH)- temporary on aspirin, history of (ICH)permanent on OAC, history of major ischemic stroke (IS), history of mild/moderate IS,
history of major hemorrhage, history of myocardial infarction (MI), history of transient
ischemic attack/systemic embolic events (TIA/SEE) and death. In the base-case analysis,
all patients begin from the healthy-with-AF health state. In each health state, patients
could experience one of the following adverse events: ICH, IS, major hemorrhage, MI,
TIA, SEE, clinically relevant non-major bleeding (CRNMB), or death from other causes.
Experiencing any of the acute event could also result in death within the month. Ischemic
stroke was categorized into major (modified Rankin Score=3-5) and mild/moderate
stroke (Figure 3.2.6.1). CRNMB was modelled as transient events after which an
individual did not change health states because there is limited evidence of direct longterm health deficits and costs associated with this adverse event.
From the healthy-with-AF health state, patients who experience an adverse event
transitioned to a health state defined by the sequelae of the event based on their most
severe event to date. We ordered health states according to the seriousness of long-term
consequences among survivors from most to least severe in the following way: ICH,
major IS, mild/moderate IS, MI, TIA/SEE and major hemorrhage (19,21,22). For
example, a patient with a history of major IS transitioned to the history of ICH health
state upon surviving an ICH. However, if, some months later, this patient experienced a
MI, the patient remained in the history of ICH health state. The patients remained in the
most severe health state until death. Major adverse events increased the risk of future
adverse events. As such, the risk of future events was adjusted for the history of most
severe adverse event to date.

3.2.3

Treatment Effectiveness

The effectiveness of alternative treatments (PGx-based warfarin, apixaban and
rivaroxaban) was implemented as hazard ratios (HRs) compared to warfarin for each
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adverse event (major hemorrhage, ICH, stroke, MI and SEE) using previously published
large randomized clinical trials and meta-analyses. The COAG trial (2014) is one of the
largest double-blinded and multicenter randomized controlled trial (RCT) that compared
pharmacogenetically based warfarin dosing with standard warfarin dosing in a cohort of
59+ year old US residents (n=1,015) (23). Findings from this trial represent the best
available evidence for the effectiveness of PGx-based care in reducing the risk of major
hemorrhage and CRNMB. The evidence of DOAC effectiveness was obtained from the
2017 National Health Services (NHS) competing risks network meta-analysis (24).
The risk of ischemic stroke was assumed to be the same under both standard and PGxbased warfarin care. Kimmel et al. (2014) did not find a significant difference in the risk
of thromboembolism, which was defined as a composite of deep venous thrombosis,
pulmonary embolism and embolic stroke (23). Similarly, Tse et al. (2018) did not find a
statistically significant difference in the risk of thromboembolism in their meta-analysis
(7). As such, the risks of IS, TIA, SE and MI were assumed to be the same under both
PGx-based and standard warfarin care in our CEA. Due to limited published evidence on
ICH, the risk of ICH was assumed to be the same under PGx-based and standard
warfarin. To summarize, the benefit of PGx-based warfarin was to reduce risks for major
hemorrhage and CRNMB by optimizing warfarin dosing using patient genotype
information.
The hazard ratios of treatment effectiveness for apixaban and rivaroxaban relative to
warfarin were mostly obtained from a NHS Health Technology Assessment 2017 study
(24). We were unable to locate credible evidence to support DOAC effectiveness in
reducing the risk of TIA; thus, we did not model treatment differences in the risk of TIAs.
The differences in the risk of major hemorrhage and CRNMB between PGx-based and
standard warfarin care were allowed for 6 months based on findings in published
literature. In a cohort study, Epstein et al. (2010) found that the reduced incidence of
bleeding or thromboembolism-related hospitalizations among patients receiving PGxbased care as compared to a matched historical control group on standard warfarin
persisted throughout the 6 months of follow-up (25). After 6 months, we assumed that the
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effect of PGx-based warfarin therapy diminished; the availability of more INR
measurements in the first 6 months led to appropriate dose adjustments under standard
warfarin therapy (26). A treatment difference lasting 3 months to 1 year was explored in
sensitivity analysis. In comparison, the risk differences between warfarin and DOACs
(apixaban and rivaroxaban) were modelled over the lifetime horizon.

3.2.4

Transition probabilities

Rates of acute adverse events for elderly AF patients on warfarin, hazard ratios indicating
treatment effectiveness and their sources are presented in Table 3.2.4.1, acute mortality
probabilities and hazard ratios for long-term mortality in Table 3.2.4.2, and hazard ratios
for the effect of previous events on future adverse events in Table 3.2.4.3.
Intracranial hemorrhage (ICH): The risk of adverse events decreases over time as
warfarin dose is optimized for each patient through re-iterative prothrombin
time/international normalized ratio (PT/INR) lab tests.5 The rate of ICH among 65-yearold Ontario residents having AF and on warfarin decreased by half after the first month
of initiating OAC treatment as compared to the rest of follow-up (27). Treatment
effectiveness on adverse event rates was modelled using hazard ratios. We assumed the
rate of ICH under standard warfarin care and PGx-based warfarin care were the same
because of limited evidence on the effectiveness of PGx-based warfarin care in reducing
the risk of ICH events. The surviving ICH patients discontinue anticoagulation and
transition to aspiring therapy for three months. Aspirin is not as effective in reducing the
risk of stroke as warfarin. As such, we increased the risk of stroke for these patients for
three months. After this period, the surviving patients resumed OAC treatment with the
same agent as they were on before the adverse event (19). Patients with an ICH incurred
a cost of acute care, disutility in the month of the event, and a possibility of death within
30 days. Patients who survived longer than one month entered a health state in which

5

The PT/INR test measures the effectiveness of warfarin in plasma by assessing time taken for blood to
clot. Under standard practice, warfarin patients are monitored through routine laboratory PT/INR testing.
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they incurred a long-term increase in costs and a reduction in utility. The surviving ICH
patients faced higher risks of future adverse events.
Ischemic stroke (IS): The real-world rate of ischemic stroke found in a cohort of Ontario
residents with AF and on warfarin decreased after the first month of OAC treatment and
reflected temporal changes in risks (28). Some strokes were fatal. The surviving stroke
cases were categorized into major and mild/moderate cases. In a Canadian-based study
by Mittmann et al. (2012), about 48.7% of surviving ischemic stroke cases had a
modified Rankin Score (mRS) between 3 to 5 at discharge and were classified as major
strokes (29). We used this study to model the proportion of major strokes among the
surviving cases and investigated the impact of varying this proportion in one-way
sensitivity analysis. An acute treatment cost of fatal and non-fatal stroke was calculated
using administrative databases at ICES Western site (Table 3.2.5.1). The surviving stroke
patients incurred an immediate reduction in quality in life. Subsequently, these patients
entered a health state in which they incurred a long-term increase in costs, reduction in
utility, and higher risks of future adverse events. Major stroke patients incurred a greater
reduction in utility and increase in long-term costs as compared to mild/moderate stroke.
Myocardial Infarction (MI): We estimated the baseline rate of MI among AF-patients
on warfarin from a Canadian-based study (8). Patients with an MI accrued a cost of acute
care, disutility, and a possibility of death in the month of the event. Patients who survived
longer than one month had an increased risk of future adverse events and non-event
death.
Transient ischemic attack/Systemic embolic events (TIA/SEE): The baseline rate of
SEE and TIA among AF-patients on warfarin was obtained from the published literature
(30,31). Patients with a TIA or SEE received a cost of acute care and disutility in the
month of the event. SEE patients had a possibility of death within 30 days. Transient
ischemic attacks are transient events and do not result in death as a direct outcome.
However, these events are indicative of increased risk of future adverse events. As such,
patients who survived a TIA/SEE experience an increased risk of future adverse events
and non-event death.
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Major hemorrhage: The real-world rate of major hemorrhage on warfarin was a
weighted average rate of upper gastrointestinal, lower gastrointestinal and other
hemorrhages rates (27). A higher rate of event was modelled in the first month of
initiating OAC treatment as compared to the rest of time horizon. Patients who had a
major hemorrhage received a one-time event cost of acute treatment, disutility in the
month of the event and probability of death within 30 days. The surviving patients
transitioned to the history of major hemorrhage health state and continued
anticoagulation therapy with the same agent as they were on before the adverse event.
Clinical evidence recommends that patients suffering a major hemorrhage should restart
anticoagulation therapy within 4-14 weeks (19). Moreover, resuming anticoagulation
therapy once the major hemorrhage event has been managed is associated with lower
mortality as compared to not resuming any anticoagulation therapy. Thus, in our model,
patients who survived major hemorrhages were assumed to have the adverse event
managed within a month and resume anticoagulation therapy by the next month/cycle.
Patients with a history of major hemorrhage had increased rates of future acute events
and mortality. Moreover, the surviving patients in this health state incurred additional
costs for one year but no long-term change in health utility.
Clinically relevant non-major bleeding (CRNMB): The baseline rate of CRNMB
among AF-patients on warfarin was obtained from a published study, which estimated
risks from the ARISTOTLE trial (32). We assumed that CRNMB could not be a fatal
adverse event. Patients with a CRNMB received a cost of acute care and disutility at the
time of the event. We assumed that a history of CRNMB did not increase the baseline
age-specific mortality rate, increase long-term costs, affect long-term quality of life, or
increase the rate of future adverse events and so individuals with a history of CRNMB
did not transition out of their current health state.
Background mortality: The age-specific mortality rates for the Ontario population were
obtained from Statistics Canada, Table 13-10-0114-01 (33). The influence of ischemic
heart diseases and cerebrovascular diseases were removed from the all-cause mortality
rates and the annual probabilities were modelled as non-event mortality in the Markov
model. The influence of prior adverse events such as ICH, major hemorrhage, MI and
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stroke were modelled by applying hazard ratios to the baseline age-specific mortality
rates.
Calibration: A patient’s age-specific mortality rate was adjusted for post-event mortality
risk (history of ICH, major IS, mild/moderate IS, MI, TIA/SEE and major hemorrhage)
using calibration to observed long-term mortality outcomes. Long-term all-cause
mortality rates after an event were obtained from published literature and the model was
calibrated to reach those targets. For example, Sennfält et al. (2019) found a cumulative
mortality rate of 62.2% at 5-years among 30-day ICH survivors with an average cohort
age of 73 years (34). We calculated the hazard ratio on baseline age-specific mortality
after ICH that was able to achieve this 5-year mortality outcome, including the risk of
death associated with the acute events that may occur within the 5-years to avoid
overcounting deaths. In this case, we estimated that individuals with a history of ICH
have a hazard ratio of 4.37 on age-specific mortality. Similarly, we performed step-wise
calibration for the most to least severe health state. The model was calibrated to reach a
cumulative 5-year death rate of 88% for patients with a history of major IS (35),
cumulative 5-year death rate of 72.8% for patients with a history of mild/moderate IS
(35), cumulative 6-year death rate of 50.3% for patients with a history of MI (36),
cumulative 5-year death rate of 29.8% for patients with a history of TIA/SEE (37) and
cumulative 2.5-year all-cause death rate of 7.5% (38).
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Table 3.2.4.1: Base-case rates for adverse events and effectiveness of treatment.
Parameter
Base-case
Range
Distribution
Low value High value
Baseline event rates under standard warfarin therapy (% per person-year)
Major
(<= 30 days)
13.3
12.9
13.7 Normal (0.133, 0.207)
hemorrhage (> 30 days)
3.4
3.33
3.47 Normal (0.034, 0.036)
ICH
(<= 30 days)
0.4
0.35
0.45 Normal (0.004, 0.026)
(> 30 days)
0.2
0.16
0.24 Normal (0.002, 0.02)
CRNMB
9.4
9.34
9.462 Normal (0.094, 0.003)
Ischemic
(<= 30 days)
6
5.55
6.45 Normal (0.06, 0.23)
stroke
(> 30 days)
1.6
1.55
1.65 Normal (0.016, 0.03)
MI
0.8
0.68
0.93 Normal (0.008, 0.06)
TIA
2.7
2.52
2.88 Normal (0.027, 0.09)
SEE
0.1
0.09
0.11 Normal (0.001, 0.004)
Stroke severity: Proportion of non-fatal strokes that are major (vs. mild/moderate) (%)
Major stroke (mRS=3-5)
48.71
42.31
55.13 Beta (113, 119)
Effectiveness of treatment (HR, with warfarin as comparator)
Major hemorrhage
PGx-based
0.41
0.13
1.31 LogNormal (-0.89,
warfarin
0.59)
Apixaban
0.72
0.62
0.82 Normal (0.72, 0.05)
Rivaroxaban
1.02
0.89
1.18 Normal (1.02, 0.07)
CRNMB
PGx-based
0.62
0.3
1.27 LogNormal (-0.48,
warfarin
0.37)
Apixaban
0.69
0.63
0.75 Normal (0.69, 0.03)
Rivaroxaban
1.04
0.96
1.13 Normal (1.04, 0.04)

Source

Gomes et al. (2013) (27)
Gomes et al. (2013) (27)
Bahit et al. (2017) (32)
Tung et al. (2015) (28)
Yu et al. (2017) (8)
SPAF III Trial, 1996 (31)
Apixaban Monograph, 2016
(30)
Mittmann et al. (2012) (29)

Kimmel et al. (2014) (23)
Sterne et al. (2017) (24)

Kimmel et al. (2014) (23)
Bahit et al. (2017) (32)
Patel et al. (2011) (39)
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ICH
Apixaban
Rivaroxaban
Ischemic stroke
Apixaban
Rivaroxaban
MI
Apixaban
Rivaroxaban
SEE
Apixaban

0.46
0.65

0.36
0.46

0.58 Normal (0.46, 0.06)
0.89 Normal (0.65, 0.11)

Sterne et al. (2017) (24)

0.9
0.92

0.72
0.73

1.11 Normal (0.90, 0.10)
1.13 Normal (0.92, 0.10)

Sterne et al. (2017) (24)

0.86
0.79

0.65
0.61

1.1 Normal (0.86, 0.11)
1.01 Normal (0.79, 0.10)

Sterne et al. (2017) (24)

0.65

0.33

1.18 LogNormal (-0.43,
0.33)
1.13 Normal (0.95, 0.09)

Sterne et al. (2017) (24)

Rivaroxaban
0.95
0.79
Ischemic stroke (HR, aspirin as comparator)
Warfarin
0.64
0.55
0.75 Normal (0.64, 0.05)
Vargas et al. (2018) (40)
Apixaban
0.59
0.37
0.73 Normal (0.59, 0.09)
Rivaroxaban
0.6
0.41
0.88 Normal (0.6, 0.12)
The differences in treatment effectiveness between PGx-based and standard warfarin care are allowed for 6 months.
There is no credible evidence of treatment impact on the risk of transient ischemic attack. As such, we did not model difference in
treatment effectiveness for this outcome.
Hazard ratios are parametrized as Normal (mean, standard error), LogNormal as (ln(mean), ln(standard error)) and beta as Beta (alpha,
beta).
PGx, pharmacogenomics; ICH, intracranial hemorrhage; CRNMB, clinically relevant non-major bleeding; MI, myocardial infarction;
TIA, transient ischemic attack; SEE, systemic embolic embolism
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Table 3.2.4.2: Base-case acute event mortality and mortality hazard ratios associated with a history of adverse event
Parameter
Base-case
Range
Distribution
Source
Low Value High Value
Acute event mortality (%)
Major hemorrhage
13.94
12.50
15.45
Beta (295, 1822)
Gomes et al. (2013) (27)
ICH
41.71
37.62
45.86
Beta (229, 320)
Gomes et al. (2013) (27)
Ischemic stroke
27.29
26.17
28.42
Beta (1639, 4367)
Tung et al. (2015) (28)
MI
28.40
27.58
29.23
Beta (3268.84,
Rathore et al. (2001) (41)
8241.16)
SEE
25.00
19.53
30.90
Beta (55.25, 165.75) Bekwelem et al. (2015) (42)
Increased mortality (hazard ratios) for patients with a history of
ICH
4.37
3.77
4.87
Normal (4.37, 0.28)
Sennfält et al. (2019) (34)*
Major IS
6.1
5.15
6.85
Normal (6.1, 0.43)
Fang et al. (2014) (35)*
Mild/moderate IS
2.76
2.1
3.48
Normal (2.76, 0.35)
MI
2.23
1.17
3.44
Normal (2.23, 0.58)
Consuegra-Sanchez et al.
(2016) (36)*
Major hemorrhage
1.2
0.87
1.6
Normal (1.2, 0.19)
(43)
TIA/SEE
1.48
1
2.33
LogNormal
Yousufuddin et al. (2018)
(0.39, 0.22)
(37)*
AF
1.15
1.02
1.33
Normal (1.15, 0.08)
Granger et al. (2011) (38)*
Beta distributions are parameterized as Beta (alpha, beta). Hazard ratios are parametrized as Normal (mean, standard error) or
LogNormal as (ln(mean), ln(standard error)).
ICH, intracranial hemorrhage; IS, ischemic stroke; MI, myocardial infarction; TIA, transient ischemic attack; SEE, systemic embolic
embolism
*Hazard ratios were calibrated to reach long-term mortality rates reported in sources.
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The effects of history of previous events on future adverse events are presented in Table
3.2.4.3. Most of this data were obtained from a Swedish study on a cohort of 182,678 AF
patients (44). The long-term risk of recurrent IS or MI among stroke or TIA survivals
were obtained from a Canadian based study (45).
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Table 3.2.4.3: Hazard ratios of effect of history of previous events on future adverse events. (95% Confidence interval) [(Reference)]
Risk Factor
ICH
Major hemorrhage
TIA/SEE
IS†
MI†
10.2
2.95
1.78
0.85
1.82
ICH
(8.59 to 12.2)
(2.57 to 3.39)
(1.56 to 2.03)
(0.61 to 1.18)
(1.62 to 2.04)
[(44)]
[(44)]
[(44)]
[(44)]
[(44)]
Major hemorrhage

3.54
(3.02 to 4.17)
[(44)]

3.32
(3.06 to 3.60)
[(44)]

IS
(Major or
mild/moderate)

1.64
(1.39 to 1.94)
[(44)]

1.39
(1.27 to 1.52)
[(44)]

MI

0.94
(0.78 to 1.12)
[(44)]

1.24
(1.15 to 1.35)
[(44)]

TIA/SEE

1.55
(1.2 to 2.0)
[(44)]

1.27
(1.1 to 1.45)
[(44)]

1.32
(1.21 to 1.44)
[(44)]

1**

8.2 (YR 1)
(7.3 to 9.3)

1.8 (YR 1)
(1.5 to 2.1)

5.9 (YR 2+)
(5.4 to 6.4)
[(45)]

1.6 (YR 2+)
(1.5 to 1.8)
[(45)]

1.24
(1.17 to 1.33)
[(44)]

1.77
(1.15 to 2.39)
[(46)]

4.6 (YR 1)
(3.9 to 5.4)

1.5(YR 1)
(1.2 to 1.9)

3.9 (YR 2+)
(3.4 to 4.3)
[(45)]

1.6 (YR 2+)
(1.4 to 1.8)
[(45)]

1.36
(1.26 to 1.46)
[(44)]
3.61
(3.44 to 3.78)
[(44)]
1.29
(1.22 to 1.36)
[(44)]
2.34
(2.18 to 2.52)
[(44)]

† Different rate ratios for Years 1 and 2+ are listed above
** Assumption because of limited evidence available in the published literature
Hazard ratios are parametrized as Normal (mean, standard error).
ICH, intracranial hemorrhage; IS, ischemic stroke; MI, myocardial infarction; TIA, transient ischemic attack; SEE, systemic embolic
embolism
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3.2.5

Cost inputs

Table 3.2.5.1 presented costs in 2017 CAD dollars using the Gross Domestic Product
deflator. Treatment costs with drug and genotyping costs are presented in Table 3.2.5.2.
Costs in foreign currency were adjusted to Canadian values using the Purchasing Power
Parity (47,48).
Each month, the surviving individuals incurred the average age-specific baseline
healthcare costs, which was obtained using the CIHI-Total Expenditure Per Capita data
for the Ontario population (49). The baseline healthcare costs were not adjusted for
potential double counting. But we do not expect double counting to have a significant
impact because the proportion of average baseline healthcare costs attributable to AF and
stroke is low since the prevalence of AF is relatively low in the general population. 6 We
also varied baseline healthcare costs to investigate their impact on CEA results in oneway sensitivity analysis.
The average incremental cost attributable to AF was added to the baseline healthcare
costs. This incremental cost included inpatient (hospitalization) and outpatient costs
(emergency visit, physician visit, laboratory services and other outpatient services)
related to causes other than modelled and non-cerebrovascular diseases in a cohort of AF
patients (See Appendix A.6.2 for the details) (50). We did not include costs related to
common cardiovascular outcomes that were modelled in our Markov model. Because this
cost was obtained from a US-based study, we adjusted for percent inflation due to the US
healthcare system. The percent US inflation was approximated by comparing the average
healthcare expenditure accrued by a 71-year-old non-AF Canadian resident to 71-yearold non-AF US patients. The average annual cost of baseline health care was capped at
$22,248.59 for patients who were 90 and older.

6

We investigated the proportion of baseline costs attributable to AF at age-specific prevalence of AF using
prevalence data among 60+ year old participants in the Framingham study (75). The CIHI-Total
Expenditure Per Capita is the sum of average non-AF and AF costs. In our sensitivity analysis, we found
that AF-attributable costs made-up about only 1-5% of age-specific Total Expenditure Per Capita when we
increased the AF-attributable costs by 40%.
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3.2.5.1

Acute care costs

Patients who had an adverse event incurred a one-time treatment cost, including
hospitalization and emergency visit costs, at the time of the event. The acute care costs
for ICH and SEE was obtained from published studies and were estimated from the
Ontario Case Costing Initiative (51,52). The hospitalization and ER visit costs for MI
were obtained from published literature as well (53).
Acute care costs for major hemorrhage, major ischemic stroke and TIA were estimated
using the ICES data (unpublished data). Using the ICES data, an Ontario populationbased cohort of newly diagnosed AF patients >65 years of age initiating anticoagulation
therapy with warfarin (n=794), apixaban (n=603) or rivaroxaban (n=534) for the first
time between January 1 st, 2012 to December 31st, 2017 were followed until March 31st,
2018, death, treatment discontinuation or treatment switch. Those patients who had
hospitalization(s) or emergency room (ER) visit(s) for each adverse event were identified
using the International Classification of Diseases and Disorders, 10th Revision (ICD-10),
diagnostic codes from the Canadian Institute for Health Information–Discharge Abstract
Database (CIHI-DAD), and the National Ambulatory Care Reporting System (NACRS)
database, respectively. Any repeated hospitalizations or ER visits within 30-days were
included to obtain a comprehensive measure of healthcare resource use and eventspecific treatment costs. We assumed that 30-day repeated admissions for the same
diagnosis were related to the previous admission. The per patient acute hospitalization
and ER visit costs were calculated by multiplying the year-specific resource intensity
weights (RIW) with the cost per weighted case (CPWC) for DAD and NACRS,
respectively, and adjusted for the consumer price index (CPI) for healthcare. 7 Fatal
adverse events were identified as cases in which death occurred at ≤ 30 days. The average

7

The RIWs are relative values that measure total patient resource use as compared to resource use during a
typical hospitalization (1). The CPWC values include the inpatient portions of emergency, ambulatory and
day surgical procedure costs as well as physician fees for admitting and discharging (1). The CPI values for
healthcare were obtained from Statistics Canada (CANSIM Table No. 18-10-0005-01) (76).
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per patient acute care cost for each adverse event and outcome at 30 days are presented in
Table 3.2.5.1.
We assumed that the acute care cost of a mild/moderate ischemic stroke is the same as a
non-fatal ischemic stroke. We also assumed that similar rehabilitative services (i.e., the
number of appointments) will be accessed after a mild/moderate IS but for a shorter
period. As such, we increased the acute care cost by a 3-month cost of ongoing care to
adjust for the turning on and off of accrued costs for this acute event. This will slightly
overcount the costs because all mild/moderate IS survivors will incur the rehabilitation
cost at the time of the event.
In the face of limited published data on CRNMB costs, the acute care cost of CRNMB
was estimated with expert input. At the time of a CRNMB, a patient may seek care from
a family physician or a specialist. Since most patients have an ongoing relationship with
their family physicians, a ratio of 3:1 was applied to reflect the interaction frequency with
GP/FP to specialist. Using this information, the average fixed cost of an encounter with a
healthcare professional was calculated. Based on published evidence, CRNMB events
were divided into the following categories; hematuria (16.4%), epistaxis (14.8%) and
non-major GI bleed (13.3%) (32). A low-end cost and high-end treatment cost for these
different types of bleeds was developed using physician input on care services and the
Ontario Schedule of Benefits for Physician Services (54). The base-case cost included the
weighted average of low-end and high-end costs. In sensitivity analysis, we varied basecase costs by assuming all low-end costs or all high-end costs were accrued. The
remaining proportion of CRNMB events, including haematoma and bruising/ecchymosis,
consisted of the average fixed cost of an encounter with a healthcare professional. The
cost components are presented in Appendix A – Table A.6.3.

3.2.5.2

Incremental care costs

The patients who survived an ICH, major hemorrhage, major ischemic stroke or MI
incurred an incremental cost of ongoing care. The ongoing costs for IS and ICH were
estimated from an Australian-based longitudinal study and included direct medical costs
for aged facilities, community services, inpatient rehabilitation, general practitioner care,
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hospitalizations for complications and other direct medical costs including specialist care,
outpatient rehabilitation, emergency department care, private allied health, respite care,
investigations, aids and modifications, ambulance transfers, and aged care assessment
teams (55). The study reported the costs incurred in the first year of the event, 3-5 years
after the event and 10-years after the event. We excluded the percent hospitalization cost
from the modelled first-year cost. The study also reported an increase in the ongoing
costs incurred from 3-5 years to 10-years but a closer look at cost components showed
that aged care facilities primarily drove this increase. The aging costs were modelled
using CIHI age-specific expenditure. As such, the 3-5 year average cost was modelled as
the incremental cost for the IS and ICH health state from year 2 and onwards. Due to
uncertainty introduced by differences in healthcare systems and time, we varied the
incremental costs by 25% in sensitivity analysis.
The patients who survived a major hemorrhage incurred an incremental cost of long-term
care for one year only. This cost was obtained from a Canadian-based study and included
cost of transfer to a rehabilitation facility, transfer to an acute or chronic hospital care,
hospitalization post discharge, long term care/nursing and home care, tests and
procedures, outpatient visits, doctor visits/other health professionals and assistive devices
or home renovations (56).8
We estimated the incremental cost associated with a history of MI based on a Canadian
study reporting 3-year health care costs before and after MI (53). Medication costs as
reported in source were excluded from all long-term costs and the cost of OAC treatment
was added manually. Although, this removes the cost of non-OAC drugs, our analysis
focuses on AF-related drug costs. We also removed any loss of productivity costs
because our analysis captures only direct medical costs incurred by the public healthcare
payer.

8

The source prospectively followed a cohort of patients in which 12% of participants were diagnosed with
AF. The reported costs may include those related to ICH. However, most of the reported cost can be
attributed to major hemorrhages other than ICH because ICH events are very rare (0.004%-0.002%) and
have high case fatality (~42%).
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Individuals who died from causes other than modelled incurred an average age-specific
incremental cost of death. This cost was estimated as the difference between the average
age-specific cost of living and cost in the year of death among a cohort of senior Ontario
residents who died between 2010 and 2012 (57).
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Table 3.2.5.1: Base-case estimates, ranges for sensitivity analysis and sources for cost inputs.
Range
Base-Case
Parameter
Distribution
(2017 CAD)
Low Value
High Value
Age-specific cost of death from other causes (annualized)
65-69
63,345
56,377
81,082
70-74
62,041
55,217
79,413
75-79
55,789
49,652
71,410
80-84
53,211
47,358
68,110
85-89
40,875
36,379
52,320
90+
40,520
36,063
51,866
Baseline age-specific health care expenditure for AF patients (annualized)
65-69
9,869
8,783
12,632
70-74
11,173
9,944
14,301
75-79
13,086
11,647
16,750
80-84
15,664
13,941
20,050
85-89
21,894
19,486
28,025
90+
22,249
19,801
28,478
Sensitivity analysis multiplier for baseline and non-event death costs
1
0.89
1.28
Gamma (2, 1)
Incremental baseline health care costs (annual) associated with specific medical history
ICH
=<12 months 13,592
10,194
16,990
Normal (13,592, 1,734)
>12 months 5,645
4,233
7,056
Normal (5,645, 720)
Major IS
=<12 months 19,702
14,776
24,627
Normal (19,702, 2,513)

Source

(49,50,57)

CIHI-National Health
Expenditure Trends (49)

Gloede et al. (2014) (55)

Gloede et al. (2014) (55)
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>12 months 4,282

3,211

5,352

Normal (4,282, 546)

Major
6,712
5,034
8,390
Normal (6,712, 856)
hemorrhage
MI
242
213
271
Normal (242, 44)
Acute adverse event costs (Fatal cases that result in death within 30 days of event)
ICH
17651
8072
30914
Gamma (9, 1,961)
CRNMB

164

144

183

Normal (164, 10)

Goeree et al. (2005) (56)
Cohen et al. (2014) (53)
Micieli et al. (2016) (51)
Appendix A – Table
A.6.3
HQO-HTA Series (52)

SEE
11,605
7,510
16,576
Gamma (27, 430)
MI
Hospitalization 12,250
10,500
14,292
LogNormal (9.41, 0.08)
Cohen et al. (2014) (53)
Emergency visit 1,826
380
8,777
LogNormal (7.51, 0.80)
Major hemorrhage
Non-fatal 3,126
2,840
3,425
Gamma (439, 7)
Calculated from ICES
databases
Fatal 4,424
2,770
6,457
Gamma (22, 202)
Major IS
Non-fatal 5,665
5,081
6,281
Gamma (343, 17)
Calculated from ICES
Fatal 7,683
6,199
9,323
Gamma (93, 83)
databases
TIA
1,412
1,175
1,671
Gamma (124, 11)
Mild/moderate IS 10,591
5,629
15,552
Normal (10,591, 2,532) *Calculated
*Sum of non-fatal Major IS and one-fourth of incremental cost after major IS
Gamma distributions are parameterized as Gamma (alpha, beta), normal distributions as Normal (mean, standard error) and lognormal
distributions as LogNormal (ln(mean), ln(standard error)).
ICH, intracranial hemorrhage; IS, ischemic stroke; MI, myocardial infarction; CRNMB, clinically relevant non-major bleeding; TIA,
transient ischemic attack; SEE, systemic embolic embolism; HQO-HTA, Health Quality Ontario Health Technology Assessment
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The monthly medication costs included the cost of drug, pharmacy dispensing fee,
physician fees and other relevant costs (Appendix A: Table A.6.4). The monthly drug
costs of warfarin, apixaban and rivaroxaban were obtained from the ODB formulary by
multiplying the unit costs with monthly dose regimes. The monthly therapy costs were
calculated by multiplying the estimated healthcare resource use with unit costs. The
healthcare resource use was quantified using clinical guidelines, published literature and
expert opinion. The unit costs were obtained from the Ontario Schedule of Benefits for
Physician Services, the Schedule of Benefits for Laboratory Services and the ODB
formulary. Long-term drug therapy costs included the cost of general cardiologist
consultation (billing code A605), general practitioner consultation (billing code A005)
and drug supply. In addition, the cost of PT/INR lab testing (billing code L445), lab
testing consultation fees (billing code G031) and long-term anticoagulation supervision
via telephone (billing code G271) were included for warfarin therapy. 9
The cost of genotyping test for four warfarin SNPs was obtained from the London Health
Science Center – Personalized Medicine clinic. The cost estimate was the sum of fixed
annualized cost of machinery (including DNA extraction equipment and software) and
variable cost of technician and reagents. The base-case cost was estimated for the total
number of patients tested at the clinic in one year (n=905). The estimated cost was varied
with a minimum cost calculated under the maximally efficient scenario. Calculations for
the number of patients tested in the maximally efficient scenario and for the hourly wage
of the technician involved genotype testing over a period of fifty-two weeks, five full
working days a week (n=13,000).

9

The cost of INR monitoring is included for warfarin therapy. In comparison, the DOACs are direct
inhibitors of the blood clot factor Xa and do not require INR/PT monitoring. As such, no INR/PT
monitoring costs were included for DOAC therapies.
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Table 3.2.5.2: Treatment costs (monthly)
Drug

Base-case
Low

Range
High

Source

282
32
26

279
29
23

286
35
29

Appendix A – Table A.6.4

343
102
122

335
94
114

351
109
130

Appendix A – Table A.6.4

331
82
110
3

325
77
104

337
88
116

Appendix A – Table A.6.4

Warfarin
1st month
2-12 month
>12 month
Apixaban
1st month
2-12 month
>12 month
Rivaroxaban
1st month
2-12 month
>12 month
Aspirin
Genotyping test

CADTH-HTA Series (58)
Personalized Medicine
84
24
500
Clinic-LHSC
LHSC, London Health Science Centre; CADTH-HTA, Canadian Agency for Drugs and
Technologies in Health – Health Technology Assessment

3.2.6

Utilities

All quality-of-life inputs are presented in Table 3.2.6.1. Priority was given to Canadian
studies using generic preference-based health utility measures from the literature. The
utility values were weighted with the average time spent in corresponding health states to
produce QALYs.
Each month, the surviving individuals incur the average age-specific health utility at
baseline, which was estimated from the general Canadian population responding to the
2013-2014 Canadian Community Health Survey (CCHS) (59). The CCHS used the
Health Utility Index III, a generic preference-based health utility measurement
instrument, to examine 8 health attributes (i.e. vision, hearing, speech, ambulation,
dexterity, emotion, cognition and pain/discomfort) on 5 or 6 levels in the general
population. The quality-of-life weights were lowered multiplicatively to account for longterm disability after an adverse event (ICH, IS and MI).
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The health utility after a major IS and ICH was approximated to the 6-month utility
reported for moderate stroke in the Oxford Vascular Study, a UK population-based study
(60). The study assessed quality of life at one month, six months, 12 months and five
years of follow-up using the EQ-5D (EuroQol-5 Dimensions) questionnaire among 73 to
75-year-old TIA or stroke patients. We chose to model the 6-month utility in our CEA
because the value reflects the long-term disability after the event without reflecting the
immediate severe effects. We assumed major IS utility for ICH patients because ICH
patients have high case fatality. As such, the most severe ICH patients will result in
immediate death and the lesser severe cases that survive will incur a utility close to major
IS patients. We approximated the long-term decrement in quality of life to be the same
for minor IS, MI and TIA patients.
At the time of an adverse event, patients experience an immediate and temporary
decrement in health, which were captured as one-time disutility. The disutilities for nonfatal major IS or ICH and mild/moderate IS or MI were estimated as the difference in
level of utility at three and six months after event (60). Disutilities are approximated as
the area under the utility curve. In this case, we reduced the 3-month change in utility in
half to approximate one-month disutility. Wang et al. (2017) reported change in EQ-5D
utility after extracranial hemorrhage and CRNMB at event onset, 3 months, 6 months, 9
months and 12 months among patients with atrial fibrillation (61). We employed the
same technique to estimate one-month disutility after a non-fatal major hemorrhage and
CRNMB.
Table 3.2.6.1: Base-case estimates, ranges for sensitivity analysis and sources for
quality-of-life inputs.
Parameter
BaseRange
Distribution
Source
Case
Low
High
Age-specific baseline health utilities (Annualized)
60-64
0.842
0.674
1
Guertin et al.
(2018) (59)
65-69
0.842
0.674
1
70-74
0.835
0.668
1
75-79
0.792
0.634
0.950
80-84
0.741
0.593
0.889
85+
0.640
0.512
0.768
Health state utility weights for patients with history of
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ICH/Major IS
Minor IS/MI

0.62
0.76

0.584
0.725

0.656
0.793

Multiplier for sensitivity analysis
1
0.8
1.2 Normal (1, 0.10)
Event-specific disutility (in the month it occurs)
CRNMB
-0.005 -0.008
-0.002 Normal (-0.005,
0.0014)
Major
-0.015 -0.022
-0.007 Normal (-0.0145,
Hemorrhage
0.0038)
Stroke/ICH
-0.060 -0.065
-0.055 Normal (-0.06,
0.0026)
Minor
-0.015 -0.020
-0.010 Normal (-0.015,
stroke/MI
0.0026)

3.2.7

LuengoFernandez et al.
(2013) (60)

Wang et al.
(2017) (61)

LuengoFernandez et al.
(2013) (60)

Deterministic sensitivity Analysis

A deterministic sensitivity analysis (DSA) was performed to evaluate model sensitivity to
input parameters. Ranges used in the DSA are listed in tables reporting base-case inputs.
The ranges were derived from 95% confidence intervals reported in source material. In
some cases, there were no 95% confidence intervals or standard errors reported. For rareevent count data, we estimated ranges by varying the number of events by assuming one
more event or one less event. For rates, we estimated ranges by deriving a standard error
around the mean (assuming a Poisson distribution). In other cases, we estimated ranges
based on variation observed across published literature. For example, we estimated drug
cost ranges by comparing ODB unit costs to the British Columbia formulary.
We varied baseline costs and non-event cost of death using a single multiplier in order to
impose correlation between the values. The multiplier was parameterized using a gamma
distribution with a mean of 1 (alpha=2, beta=1) and evaluated the area under the curve at
25th and 97.5th percentile to provide values for the deterministic sensitivity analysis.

3.2.8

Probabilistic sensitivity analysis

A probabilistic sensitivity analysis was performed using Monte Carlo simulation
technique with 3000 replications. Distributions were specified using the reported means
and 95% confidence intervals, standard errors or other distribution parameters obtained
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from sources. When the statistical analysis used in the primary analysis assumed a
Normal distribution around the estimated mean or the 95% confidence interval provided
was relatively symmetric around the mean, we used normal distributions to capture
uncertainty around the mean estimates. Uncertainty around the mean is often normally
distributed by the Central Limit Theorem. If the confidence interval was not symmetric,
we transformed data on the LogNormal scale to test if we satisfy the normality
assumption and used a LogNormal distribution. We used beta and gamma distributions
for proportions and skewed costs, respectively.

3.2.9

Model validation

Formal internal validation was conducted by testing the mathematical logic of the model,
verifying equations for the first 10 stages in the full Markov trace and comparing extreme
input values with expected results as a quality assurance measure of coding and model
development. We confirmed the 5-year background mortality rate as predicted from the
model (~11%) with expected mortality rate (~12%) from the Canadian life table.
Model validation was also conducted by populating model with data parameters found in
published studies. When we populated our model with data parameters used by Shah et
al. (2016), patients under apixaban lived an average of 9.96 QALYs (9.38 QALYs in the
original study), 9.68 QALYs under rivaroxaban (9.24 QALYs in the original study) and
9.52 QALYs (9.02 QALYs in the original study) under standard warfarin care (62). The
differences in results can be attributed to some structural differences between our model
and published models. Shah et al. (2016) assumed death after 2 major events and
transition to a severe health state after 2 minor neurological events. In contrast, our model
predicts patients reach a worse-off health state upon experiencing an adverse event more
severe than present history. Patients remain in the more severe health until death or the
next event worse in magnitude. As such, patients in our model live slightly longer
because we did not assume death for these patients after 2 major events.
The average LYs and QALYs accrued under warfarin care and apixaban in our model are
similar to those reported in published literature. In our model, patients had an average life
expectancy of 78.46 years under warfarin, 78.75 years under rivaroxaban and 78.93 years
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under apixaban. When adjusted for quality of life, patients had an average life expectancy
of 75.59 years under warfarin, 75.82 under rivaroxaban and 75.96 years under apixaban.
Similarly, in the CEA by Dilokthornsakul et al. (2019), patients had an average life
expectancy of 77.28 years under warfarin, 77.49 years under rivaroxaban and 77.75 years
under apixaban for a cohort of 68-year-old Thai AF patients (and the study used most of
the same effectiveness parameters as our model) (10). When adjusted for quality of
life, patients had an average life expectancy of 74.98 years under warfarin, 75.20 years
under rivaroxaban and 75.42 years under apixaban. Shah et al. (2016) also reported an
average life expectancy of 78.02 QALYs for patients under warfarin, 78.24 QALYs
under rivaroxaban and 78.38 years under apixaban for a cohort of 69-years-old AF US
patients (unadjusted life expectancy not reported in study) (62).

3.3 Results
3.3.1

Base-case Analysis

In our model, the cohort of 65-year-old AF patients lived an additional 13.46 years under
standard warfarin care, 13.50 years under PGx-based warfarin care, 13.75 years under
rivaroxaban and 13.93 years under apixaban. When adjusted for quality of life, AF
patients accrued an additional 10.59 QALYs under standard warfarin care, 10.63 QALYs
under PGx-based warfarin care, 10.82 QALYs under rivaroxaban and 10.96 QALYs
under apixaban (all discounted). Over the lifetime horizon, patients accrued about
$217,977 under standard warfarin care, $218,560 under PGx-based warfarin care,
$235,537 under rivaroxaban and $240,351 under apixaban (all discounted) (Table 3.3.1).
Two comparisons of the base-case results are reported. First, PGx-based warfarin care,
apixaban and rivaroxaban, were compared to the reference treatment strategy of standard
warfarin care. Second, all OAC treatment strategies were ranked in terms of increasing
effectiveness and sequential comparisons were made. Standard warfarin care was ranked
the lowest in effectiveness because it produced the least number of QALYs and lifeyears, while apixaban was ranked the highest in effectiveness because it produced the
highest QALYs and life-years.
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Table 3.3.1: Number of acute events per cohort of 10,000 patients aged 65 years accrued
over 5 years, average life expectancy, average lifetime discounted costs and QALYs, and
ICER for alternative oral anticoagulation treatments in AF patients from the public
healthcare payer perspective.
Strategy
Outcomes
Standard
PGx-based
Rivaroxaban
Apixaban
warfarin
warfarin
Time horizon – 5 years
1,034
1,034
949
926
IS, n
111
109
72
50
ICH, n
916
752
937
650
Major hemorrhage, n
2,890
2,722
3,016
2,010
CRNMB, n
397
398
314
343
MI, n
1,456
1,454
1,455
1,453
TIA, n
54
54
51
35
SEE, n
Time horizon – lifetime
Average life
13.46
13.50
13.75
13.93
expectancy, yrs
Average lifetime costs
217,977
218,560
235,537
240,351
(discounted), $
Average lifetime
10.59
10.63
10.82
10.96
QALYs (discounted)
Comparison to standard warfarin
Incremental costs, $
Reference
583
17,560
22,373
Incremental QALYs,
0.03
0.23
0.37
Reference
(months)
(0.36 months) (2.76 months) (4.44 months)
ICER ($/QALY
Reference
$17,727
$78,020
$60,649
gained)
Excluding dominated
Incremental costs, $
Reference
583
N/A
21,790
Incremental QALYs,
0.03 (0.36
0.34 (4.08
Reference
N/A
units (months)
months)
months)
ICER ($/QALY
Ext.
Reference
17,727
64,853
gained)
Dominated
ICER, incremental cost-effectiveness ratio; PGx, Pharmacogenomics; Ext, Extended;
ICH, intracranial hemorrhage; IS, ischemic stroke; MI, myocardial infarction; CRNMB,
clinically relevant non-major bleeding; TIA, transient ischemic attack; SEE, systemic
embolic embolism.
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3.3.1.1 Comparison to standard warfarin care
Patients under standard warfarin care had the shortest life expectancy. In a cohort of
10,000 patients, there were approximately 1,034 ischemic strokes, 111 ICHs, 916 major
hemorrhages and 2,890 CRNMB events within 5 years of initiating standard warfarin
therapy (Table 3.3.1). PGx-based warfarin care was slightly more effective and costlier
than standard warfarin. Patients accrued an additional 0.25 years (3 months), 0.03
QALYs (~11 days) and $583 under PGx-based warfarin care as compared to standard
warfarin care. In a cohort of 10,000 patients, there were approximately 1,034 ischemic
strokes, 109 ICHs, 752 major hemorrhages and 2,722 CRNMB events within 5 years of
initiating PGx-based warfarin therapy. Overall, there were 2 fewer ICHs, 164 fewer
major hemorrhages and 167 fewer CRNMB events under PGx-based warfarin care as
compared to standard warfarin care. Over the lifetime horizon, the incremental cost per
QALY gained under PGx-based warfarin was $17,727/QALY.
As compared to standard warfarin care, treatment with DOACs was more effective but
also more expensive. Apixaban and rivaroxaban increased costs by about $22,373 and
$17,560, respectively. In terms of effectiveness, apixaban and rivaroxaban increased
QALYs by about 0.37 units (~4.44 months) and 0.23 units (~2.76 months), respectively.
In a cohort of 10,000 patients, there were approximately 926 ischemic strokes, 50 ICHs,
650 major hemorrhages and 2,010 CRNMB events within 5 years under apixaban. As
compared to standard warfarin, there were 108 fewer ischemic strokes, 61 fewer ICHs,
266 fewer major hemorrhages and 880 fewer CRNMB events under apixaban. If the
cohort of 10,000 patients started treatment with rivaroxaban, there were 85 fewer strokes
and 39 fewer ICHs as compared to standard warfarin. However, there were 20 additional
major hemorrhages and 125 additional CRNMB events within 5 years of initiating
rivaroxaban treatment as compared to standard warfarin. The incremental cost per QALY
gained under apixaban and rivaroxaban was $60,649/QALY gained and $78,020/QALY,
respectively.
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3.3.1.2 Excluding dominated strategy
When treatments were ranked in order of increasing effectiveness, rivaroxaban was
dominated by the principle of extended dominance (Figure 3.3.1).10 The undominated
strategies, in order of increasing effectiveness and costs, were standard warfarin care,
PGx-based warfarin care and apixaban. Apixaban increased lifetime costs by $21,790 and
QALYs by 0.34 units (~4.08 months) as compared to PGx-based warfarin care. It costed
about $64,853 to gain one additional QALY under apixaban as compared to PGx-based
warfarin.

Figure 3.3.1: Cost-effectiveness plane. Incremental costs and QALYs comparing
alternative oral anticoagulation treatments with standard warfarin care.
SW, standard warfarin; PGx, Pharmacogenomics (PGx)-based warfarin; R, rivaroxaban;
A, apixaban; QALY, quality-adjusted life-years

10

A strategy is dominated by the principle of extended dominance if it costs more and provides fewer
QALYs than a linear combination of two other alternatives.
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3.3.2

Deterministic Sensitivity Analysis Results

The results of the deterministic sensitivity analysis are presented in Table 3.3.2.
Table 3.3.2: Incremental cost-effectiveness ratio ($/QALY gained) of alternative oral
anticoagulation strategies as compared to standard warfarin care.
PGx-based
Rivaroxaban
Apixaban
warfarin
Base-case
17,727
Ext. Dominated
64,853
Discounting
0%
19,136
Ext. Dominated
62,829
3%
16,439
Ext. Dominated
67,214
Patient Characteristics
Age (yrs) at initiating OAC treatment
70
20,492
Ext. Dominated
76,547
75
24,343
Ext. Dominated
92,659
80
29,562
Ext. Dominated
114,187
85
35,614
Ext. Dominated
139,700
Baseline Health
Substantially above-average
health (Baseline utilities
increased by 20%, costs
15,981
Ext. Dominated
98,024
decreased by 10%, event rates
decreased by 50%*)
Above-average health
(Baseline utilities increased
by 10%, costs decreased by
16,337
Ext. Dominated
72,946
5%, below-average event
rates**)
Below-average health
(Baseline utilities decreased
by 10%, costs increased by
19,893
Ext. Dominated
55,287
10%, above-average event
rates**)
Substantially below-average
health (Baseline utilities
decreased by 20%, costs
24,872
Ext. Dominated
58,262
increased by 28%, event rates
doubled*)
Medical history (History of an adverse event)
Hx of ICH
34,316
Ext. Dominated
70,002
Hx of major ischemic stroke
37,994
Ext. Dominated
97,332
Hx of minor ischemic stroke
23,762
Ext. Dominated
59,103
Hx of myocardial infarction
22,696
Ext. Dominated
50,931
Hx of TIA/SEE
22,565
Ext. Dominated
80,541
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Hx of major hemorrhage
15,430
Ext. Dominated
47,347
Risks and treatment effectiveness
Treatment difference between PGx-based warfarin and standard warfarin (Base-case=6 months)
3 months
19,057
Ext. Dominated
63,782
12 months
16,748
Ext. Dominated
67,084
Low OAC effectiveness (HRs=95% CI upper bounds)
46,257
PGx-based warfarin
***
Ext. Dominated
(ICER- compared to
Standard warfarin)
Dominated by
Rivaroxaban
17,727
PGx-based
64,853
warfarin
Dominated by PGxApixaban
17,727
88,344
based warfarin
High OAC effectiveness (HRs=95% CI lower bounds)
PGx-based warfarin
16,949
Ext. Dominated
76,727
Rivaroxaban
17,727
42,210.38
Ext. Dominated
Apixaban
17,727
Ext. Dominated
41,240
Patient susceptibility to adverse events
Higher than average (Upper
ranges of event rates, future
17,694
Ext. Dominated
58,382
risks and non-event death)
Lower than average (lower
ranges of event rates, future
17,083
Ext. Dominated
74,933
risks and non-event death)
Costs
Baseline costs
11% lower
15,557
Ext. Dominated
62,263
28% higher
23,250
Ext. Dominated
71,445
PGx test cost (Base-case=$84.00)
24.05
15,812
Ext. Dominated
65,040
145
19,489
Ext. Dominated
64,680
200
21,161
Ext. Dominated
64,517
500
30,279
Ext. Dominated
63,623
1000
45,475
Ext. Dominated
62,136
PGx-test in patients with high baseline costs (increased by 28%)
Low PGx test cost ($24)
21,335
Ext. Dominated
71,632
High PGx test cost ($145)
25,013
Ext. Dominated
71,272
st
nd
th
Low apixaban cost (1 month=$335, 2 – 12 month=$94, 12+ months=$114) vs. PGx test cost
Low PGx test cost ($24)
15,812
Ext. Dominated
61,140
High PGx test cost ($145)
19,489
Ext. Dominated
60,780
High acute and ongoing costs (upper ranges) for patients with a medical history of
ICH
37,200
Ext. Dominated
66,843
Major IS
40,379
Ext. Dominated
99,069
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MI
22,850
Ext. Dominated
50,590
Utilities
Baseline utilities
10% lower
22,109
Ext. Dominated
80,865
20% lower
19,677
Ext. Dominated
71,979
Low health utilities (lower ranges) for patients with a medical history of
Major hemorrhage
16,522
Ext. Dominated
51,924
Major IS
40,282
Ext. Dominated
104,878
MI
22,751
Ext. Dominated
50,758
PGx-test in patients with low baseline health utilities (decreased by 10%)
Low PGx test cost ($24.05)
17,551
Ext. Dominated
72,187
High PGx test cost ($145.00)
21,633
Ext. Dominated
71,788
*The event rates were varied based on risks observed by patients on different CHADS2
scores in the literature.11
**Above average event rates were the average of base rates and doubled rates. Belowaverage were the average of base rates and rates reduced in half.
***Standard warfarin accrues higher costs and QALYs than PGx-based warfarin at an
ICER of $10,024/QALY.
The CEA results were sensitive to patient characteristics (Table 3.3.2). In particular, the
results were highly sensitive to start age. As the OAC therapy starting age increased, the
lifetime accrued costs and QALYs decreased across all OAC strategies and the
differences between strategies decreased. As a result, the ICER values increased among
the undominated strategies (standard warfarin, PGx-based warfarin and apixaban). The
ICER values increased more sharply for apixaban as compared to PGx-based warfarin
(Figure 3.3.2.1). Apixaban reached a maximum ICER of $139,700/QALY gained and
PGx-based warfarin reached a maximum ICER of $35,614/QALY if start age of OAC
therapy was 85 years.
There is heterogeneity in the baseline health of 65-year-old AF patients based on
comorbidities that are not explicitly accounted for in the model. We explored the
‘healthy’ and ‘less healthy’ individuals by simultaneously varying their baseline

11

The base-case rate of ischemic stroke was almost double the event rate reported for patients with a
CHADS2 score of 2 and half the event rate reported for patients with a CHADS2 score of 4&6 (62). As
such, we doubled or reduced in half the event rates to explore the impact of patients with substantiallybelow or -above average baseline health on ICERs in sensitivity analysis. Please note our analysis did not
include CHADS2 score directly in the Markov model.

76

healthcare costs, baseline utilities, and baseline event rates. For a cohort of healthier than
average 65-year old patients, a group with lower than average baseline costs and event
rates and higher than average baseline utilities, we found the ICER for PGx-based
warfarin compared to standard warfarin decreased from $17,727/QALY to
$16,337/QALY and the ICER of apixaban compared to PGx-guided warfarin increased
from $64,853/QALY to $72,946/QALY. For slightly below-average healthy individuals,
ICER for PGx-based warfarin compared to standard warfarin increased from
$17,727/QALY to $19,893/QALY and the ICER of apixaban compared to PGx-guided
warfarin decreased from $64,853/QALY to $55,287/QALY. When we considered a more
extreme scenario in which baseline health care costs were increased by 28%, baseline
utilities were decreased by 20%, and baseline risks of adverse events were doubled, we
found that among substantially below-average healthy patients, the ICER of apixaban
increased again. This scenario corroborates what was seen in the sensitivity analysis on
starting age of OAC initiation. With higher rates of competing mortality, which results in
smaller incremental benefits, more expensive treatment corresponds to higher ICERs.
We approximated higher patient susceptibility to adverse events by assuming higher
event rates, risk of future adverse events and non-event death. In this scenario, the cost
per QALY gained decreased to $58,382 under apixaban as compared to PGx-based
warfarin. In contrast, when lower patient susceptibility was assumed, the cost per QALY
increased to $74,933 under apixaban as compared to PGx-based warfarin. The ICER
value for PGx-based warfarin was not very influenced by patient susceptibility and
remained around $17,000/QALY gained.
The CEA results were sensitive to patient medical history of adverse events. The ICERs
increased by a large magnitude for patients who had a history of major ischemic stroke,
ICH and TIA/SEE. For these patients, it costed more to gain one additional QALY under
PGx-based warfarin and apixaban as compared to the average person in base-case. For
patients who had a history of minor ischemic stroke and myocardial infarction, the ICERs
increased for PGx-based warfarin and decreased under apixaban treatment. For these
patients, it costed more to gain one additional QALY under PGx-based warfarin and less
to gain one additional QALY under apixaban as compared to base-case. For patients with
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a history of major hemorrhage, it costed less to gain one additional QALY as compared
to what it costed in the base-case under both PGx-based warfarin and apixaban.
The general trend was that ICERs increased with age for all medical histories. The ICERs
increased sharply for older apixaban patients with a history of major IS, ICH and
TIA/SEE as compared to PGx-based warfarin (Figure 3.3.2.3).
The results were very sensitive to treatment effectiveness of PGx-based warfarin care.
When low effectiveness of PGx-based warfarin was assumed (i.e. it was less effective
than standard warfarin care), patients under standard warfarin accrued higher costs and
QALYs. It costed about $10,024 to gain one additional QALY under standard warfarin as
compared to PGx-based warfarin. The lower effectiveness of PGx-based warfarin was
due to increased risk of major hemorrhage and CRNMB events during the first sixmonths of OAC therapy. Assuming lower effectiveness of PGx-based warfarin also
decreased the ICER for apixaban and it costed about $46,257 to gain one additional
QALY under apixaban treatment as compared to standard warfarin. When high PGxbased warfarin effectiveness was assumed, patients under PGx-based accrued higher
costs and QALYs than standard warfarin. It costed about $16,949 to gain one additional
QALY under PGx-based warfarin as compared to standard warfarin care. The ICER for
apixaban increased and it costed about $76,728 to gain one additional QALY under
apixaban as compared to standard warfarin.
In the base-case analysis, rivaroxaban was ruled out through the principle of extended
dominance. Although it decreased the risk of IS and ICH, patients experienced higher
risks of major hemorrhage and CRNMB under rivaroxaban as compared to standard
warfarin. When low rivaroxaban effectiveness was assumed and patients experienced
increased risk of all adverse events, patients accrued higher costs and lower QALYs, and
rivaroxaban was absolutely dominated by PGx-based warfarin. In contrast, when higherthan-average rivaroxaban effectiveness was assumed, rivaroxaban dominated apixaban
through the principle of extended dominance and it costed about $42,210 to gain one
additional QALY under rivaroxaban as compared to PGx-based warfarin.
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When lower apixaban effectiveness was assumed, PGx-based warfarin dominated
apixaban and rivaroxaban also became an undominated option. Under this scenario, it
costed about $88,344 to gain one additional QALY under rivaroxaban as compared to
PGx-based warfarin. In contrast, when high apixaban effectiveness was assumed, the cost
to gain one additional QALY decreased to $41,240 under apixaban as compared to PGxbased warfarin.
In the base-case scenario, we assumed a six-month treatment difference between PGxbased warfarin and standard warfarin. We assumed that more INR measurements and
dose adjustments under standard warfarin will diminish the added benefit of PGx-based
warfarin care. We investigated the impact of this assumption on the CEA results. We
found that the ICER value for PGx-based warfarin increased to $19,057/QALY gained if
treatment difference was reduced to 3 months. Consequently, the ICER value for
apixaban decreased to $63,782/QALY gained. On the other hand, the ICER value for
PGx-based warfarin decreased to $16,748/QALY gained if treatment difference was
increased to 12 months. Consequently, the ICER value for apixaban increased to
$67,084/QALY gained.
The cost of PGx test influenced the ICER values for PGx-based warfarin. Under the
assumption of maximally efficient scenario, we calculated a cost of $24.05 per PGx test
at the Personalized Medicine Clinic at LHSC. In this scenario, the cost to gain one
additional QALY decreased to $15,812 under PGx-based warfarin as compared to
standard warfarin. However, the ICER values increased as PGx test cost increased. The
cost to gain one additional QALY increased to $45,475 if PGx test cost was increased to
$1,000 per patient. Rivaroxaban was ruled out by principle of dominance and the ICER
for apixaban did not change by a large magnitude across all PGx-test costs. The general
trend was that the ICER for PGx-based warfarin as compared to standard warfarin
increased sharply and ICER for apixaban as compared to PGx-based warfarin decreased
gradually as PGx test prices increased. The increasing PGx test prices did not affect the
clinical effectiveness of treatments and therefore, the ranking of strategies. Patients under
apixaban accrued higher QALYs than PGx-based warfarin and patients under PGx-based
warfarin accrued higher QALYs than standard warfarin. Higher PGx-test prices increased
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the lifetime costs, incremental costs and ICERs under PGx-based warfarin as compared
to standard warfarin care. However, PGx test prices did not affect the lifetime costs
accrued under apixaban as compared to PGx-based warfarin. As such, the ICERs for
apixaban as compared to PGx-based warfarin gradually decreased as PGx test prices
increased. The incremental cost per QALY gained under PGx-based warfarin as
compared to standard warfarin surpassed the ICER under apixaban as compared to PGxbased warfarin at a genotype test price of $1,500/patient or higher (Figure 3.3.2.4).
We investigated the impact of baseline costs alone and found that the CEA results were
sensitive to baseline costs. We found that the ICER for PGx-based therapy decreased to
$15,557/QALY gained if we reduced baseline costs by 11% and increased to
$23,250/QALY gained if we increased baseline costs by 28%. Similarly, the ICER for
apixaban decreased to $62,263/QALY gained if we reduced baseline costs by 11% and
increased to $71,445/QALY gained if we increased baseline costs by 28%.
We investigated the sensitivity of CEA results to PGx-test cost and baseline costs. In
patients with higher baseline costs, the ICER values increased to $21,335/QALY gained
if we assumed low PGx-test cost of $24 under the maximally efficient scenario and to
$25,013/QALY gained if we assumed higher-end PGX-test cost of $145 per patient.
Generally, the ICER values increased as baseline costs and PGx-test costs increased.
The CEA results were sensitive to acute and ongoing costs for patients with a medical
history of ICH, major IS and MI. For these patients, the ICERs increased and it costed
more to gain one additional QALY under both PGx-based warfarin and apixaban as
compared to base case. However, for patients with a history of MI, it costed less to gain
one additional QALY under apixaban as compared to base case.
The CEA results were sensitive to baseline utilities. It generally costed more to gain one
additional QALY if baseline utilities were lowered. The ICER increased to
$19,677/QALY if baseline utilities were lowered by 10% and $22,109/QALY if baseline
utilities were lowered by 20% under PGx-based therapy. The ICER increased to
$71,979/QALY if baseline utilities were lowered by 10% and $80,865/QALY if baseline
utilities were lowered by 20% under apixaban. In patients with 10% lower baseline
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health utility, the cost to gain one additional QALY decreased to $17,551 at low-end PGx
test cost and increased to $21,633 at high-end PGx test cost.
The ICERs increased to $40,282/QALY gained under PGx-based warfarin and to
$104,878/QALY gained under apixaban for patients with a major IS and accruing lowend health state utilities after an adverse event as compared to base case. In comparison,
the ICERs decreased to $16,522/QALY gained under PGx-based warfarin and to
$51,924/QALY gained under apixaban for patients with a history of major hemorrhage
and accruing low-end health state utilities after an adverse event as compared to base
case. For patients with a history of MI, the cost to gain one additional QALY increased to
$22,751 under PGx-based warfarin and decreased to $50,758 under apixaban.
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Figure 3.3.2.1: ICER indicates the cost to gain one additional QALY under apixaban as
compared to PGx-based warfarin and under PGx-based warfarin as compared to standard
warfarin care at different OAC therapy starting ages.
QALY, quality-adjusted life-years; PGx, Pharmacogenomics; OAC, oral anticoagulation
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Figure 3.3.2.2: ICER indicates the cost to gain one additional QALY at different baseline
health status under apixaban as compared to PGx-based warfarin and under PGx-based
warfarin as compared to standard warfarin care.
QALY, quality-adjusted life-years; PGx, Pharmacogenomics
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Figure 3.3.2.3: ICER indicates the cost to gain one additional QALY for patients with a
history of adverse event and across different ages.
Dotted line represents ICERs under apixaban as compared to PGx-based warfarin and
dashed line represents ICERs under PGx-based warfarin as compared to standard
warfarin care.
Hx, history; ICH, intracranial hemorrhage; IS, ischemic stroke; MI, myocardial
infarction; TIA, transient ischemic attack; SEE, systemic embolic events; QALY, qualityadjusted life-years; PGx, Pharmacogenomics
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Figure 3.3.2.4: ICERs of apixaban as compared to PGx-based warfarin and ICERs of
PGx-based warfarin as compared to standard warfarin care across increasing PGx test
prices.
QALY, quality-adjusted life-years; PGx, Pharmacogenomics

3.3.3

Probabilistic Sensitivity Analysis Results

Figure 3.3.3.1: Cost-effectiveness acceptability curves (the percent of iterations in which
each treatment strategy is a cost-effective option at various WTP) thresholds).
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The probabilistic sensitivity analysis (PSA) results were summarized using costeffectiveness acceptability curves in Figure 3.3.3.1. The results showed that all four
treatment strategies were potentially cost-effective at some percentage of the time across
the range of WTP values. At the WTP threshold of $50,000/QALY gained, PGx-based
warfarin was the cost-effective treatment in 51.5% of the iterations, followed by standard
warfarin in 30.7% of iterations, apixaban in 14.1% of iterations and rivaroxaban in about
3.7% of iterations. At the WTP threshold of $100,000/QALY gained, apixaban was the
cost-effective treatment in 54.7% of the iterations, followed by PGx-based warfarin in
22.8% of iterations, rivaroxaban in 18% of iterations and standard warfarin in about 4.5%
of iterations. At the WTP threshold of $150,000/QALY gained, apixaban was the costeffective treatment in 70.1% of the replications, rivaroxaban in 23.3% of iterations, PGxbased warfarin care in 5.7% of iterations and standard warfarin care in only 0.9% of
iterations.
We investigated the robustness of PSA results to patient age and medical histories. The
ranking of OAC strategies at the WTP threshold of $150,000/QALY did not change when
patients started OAC treatment at an older age or had a history of major IS, minor IS or
TIA/SEE (Appendix B: Supplementary PSA Results).

3.4 Discussion
Our CEA results indicate that PGx-based warfarin care, apixaban and rivaroxaban
improve the health of AF patients by reducing the risk of ischemic strokes and major or
intracranial bleeding as compared to standard warfarin. However, alternative OAC
strategies also increase lifetime costs when compared to standard warfarin. Both PGxbased warfarin and apixaban lie on the cost-effectiveness frontier and can be costeffective at some willingness-to-pay (WTP) thresholds. However, rivaroxaban lies above
the cost-effectiveness frontier. Clinical trial data have shown that rivaroxaban increases
the risk of major and clinically relevant non-major bleeding as compared to standard
warfarin. As such, rivaroxaban is dominated by apixaban through extended dominance.
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3.4.1

Apixaban and rivaroxaban versus standard warfarin care

Our findings indicate that the DOACs are more effective and expensive than standard
warfarin care. In the base-case analysis, 65-year old AF patients accrued an average of
10.59 QALYs under standard warfarin, 10.82 QALYs under rivaroxaban and 10.96
QALYs under apixaban. Rivaroxaban increased QALYs by 0.23 units (~2.76 months)
and costs by $17,560. In comparison, apixaban increased QALYs by 0.37 units (~4.44
months) and costs by $22,374. It costed about $78,020 to gain one additional QALY if all
AF patients in our hypothetical cohort were treated with rivaroxaban as compared to
standard warfarin. In comparison, it costed about $60,649 to gain one additional QALY if
all AF patients in our hypothetical cohort were treated with apixaban as compared to
standard warfarin.
Our results on the cost-effectiveness of DOACs versus standard warfarin care are
consistent with findings in the published literature. Several studies have found the
DOACs to be more costly and more effective as compared to standard warfarin care in
the context of Canada, US, France and UK (16,24,62–65). Coyle et al. (2013) found that
AF patients in Canada accrued higher QALYs under the DOACs as compared to standard
warfarin. In their study, patients had an average gain of 6.48 QALYs under standard
warfarin, 6.62 QALYs under apixaban and 6.54 QALYs under rivaroxaban. The lower
lifetime QALYs in their study as compared to our study can be explained by differences
in the age of target population. As the starting age of OAC treatment increased, the
lifetime and incremental QALYs decreased in our one-way sensitivity analysis. The
target population in our CEA is younger than in most published CEAs, which may
explain the higher QALYs accrued in our CEA. In the Coyle et al. (2013) study, the
target population had an average age of 72 years. In comparison, the target population in
our CEA had an average age of 65 years, which is the age at which OAC treatments are
funded by the MOHLTC under the ODB formulary. On average, the AF patients had a
life expectancy of 75 years in our CEA and 78 years in the Coyle et al. (2013) study.
Among the DOACs, apixaban treatment led to highest QALYs when compared to
standard warfarin both in our and published studies.
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The lifetime costs and incremental cost estimates in our analysis are higher than
previously reported estimates (15,16,62). Our CEA includes the average age-specific
healthcare costs at baseline incurred by Ontario patients with AF and non-event death
costs. Stroke prevention through OAC treatments shifts the cause of death from
cardiovascular diseases (such as ischemic stroke) to other age-specific causes (40). Other
studies understate the costs attributable to life-extending interventions by assuming low
baseline healthcare costs and making non-event death free of cost. Our CEA captures the
cost of extended life expectancy and death from causes other than modelled.

3.4.2

PGx-based warfarin versus standard warfarin care

To date, published studies on the cost-effectiveness of PGx-based warfarin therapy
compared to standard warfarin have produced conflicting results; three studies found
PGx-based warfarin care was cost-effective, five found PGx-based warfarin care was not
cost-effective and four were inconclusive (66). Although PGx-based warfarin care has
been found to be cost-effective in the context of Sweden and the UK, a previous
Canadian study found that PGx-based warfarin care led to large increase in costs and
small increase in QALYs (15,65). Nshimyumukiza et al. (2013) found that PGx-based
warfarin increased costs by $460 and QALYs by only 0.0085 units (~3 days). With an
ICER of $54,118/QALY gained, the authors concluded PGx-based warfarin was not costeffective as compared to standard warfarin care at a WTP threshold of $50,000/QALY. In
comparison, our study found that PGx-based warfarin increased costs by $583 and
QALYs by 0.03 units (~11 days). It costed about $17,727/QALY gained under PGxbased warfarin as compared to standard warfarin therapy. Our CEA found that PGxbased warfarin increases QALYs by a larger magnitude and can be cost-effective at lower
WTP thresholds than previously suggested. Nshimyumukiza et al. (2013) did not
consider treatment effectiveness for clinically relevant minor thromboembolic and
hemorrhagic events in their analysis. In contrast, we included the effectiveness of PGxbased warfarin in reducing the risk of CRNMB events, in addition to major hemorrhagic
events in our analysis. As such, our CEA provides a more comprehensive approach by
capturing the added benefit of PGx-based warfarin in reducing CRNMB events which are
much more prevalent than major hemorrhage.
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As compared to published CEAs that found PGx-based warfarin to be cost-effective at
WTP thresholds higher than $20,000/QALY, we captured CRNMB events separately
from major bleeding events because the treatment cost for each type of bleeding is very
different. Major bleeding events are considered to lead to hospitalization and can cost
between $10,819 to $22,355 (67). In comparison, CRNMB events do not require
intensive treatment and typically cost approximately $100 per event (51). Including major
hemorrhage and CRNMB events as one cluster would have produced biased cost
estimates.
Previous CEAs have stratified the risk of adverse events by INR ranges in their analysis
(65,68). For example, Patrick et al. (2009) first stratified patients into INR ranges and
modelled INR-specific adverse event rates for the first 3-months (68). In comparison, we
modelled the overall risk of adverse events using clinical trial evidence and avoided
making assumptions about the time it takes for intermediate outcomes such as INR
ranges to be translated into clinically relevant adverse events.
Finally, previous CEAs in the context of US and Canada have used a genotyping cost of
about $500-$800 (15,65,68). In comparison, the cost for a genotyping test in our CEA
was estimated to be $87 per patient, which was obtained from the LHSC-PM clinic.
Using latest effectiveness and cost data, our CEA found that PGx-based warfarin care can
be cost-effective at WTP thresholds of $20,000/QALY and higher as compared to
standard warfarin.

3.4.3

PGx-based warfarin versus apixaban

Treatment with rivaroxaban resulted in lower incremental QALYs and higher incremental
costs than apixaban. As such, rivaroxaban was ruled out by extended dominance because
decision makers prefer the more effective intervention with a lower ICER. Among the
undominated strategies, PGx-based warfarin was cost-effective at WTP thresholds of
$20,000/QALY or higher and apixaban was cost-effective at WTP thresholds of
$65,000/QALY gained or higher. Previous studies that compared PGx-based warfarin
and DOACs with standard warfarin report similar findings. PGx-based warfarin and
apixaban provide a net clinical benefit to patients, increasing quality-adjusted life
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expectancy as compared with standard warfarin (13–16). Moreover, PGx-based warfarin
results in small increase in QALYs and large increase in costs.
Two previous Canadian CEAs recommended dabigatran 150 mg as the optimal OAC
strategy. Dyspepsia is a common adverse event associated with dabigatran use. These
studies did not include the impact of dyspepsia on incremental costs and quality of life in
their analyses. We excluded dabigatran from our CEA because of its limited uptake in
current clinical practice (9). Nshimyumukiza et al. (2013) found PGx-based warfarin was
not cost-effective at the WTP threshold of $50,000/QALY gained in Canada (15). In
contrast, our CEA finds that PGx-based warfarin can be cost-effective at this threshold at
a real-world genotyping test cost of $87 per patient. In a CEA of DOACs, Coyle et al.
(2013) assumed the drug cost of apixaban to be the same as dabigatran because apixaban
was not covered by the ODB formulary at the time of their study (16). Importantly, our
CEA improves on the previous study by including the current drug costs incurred by the
MOHLTC through the ODB formulary and treatment effectiveness in reducing the risk of
clinically relevant non-major bleeding. As mentioned above, CRNMB events are more
prevalent than major bleeding events. Moreover, there is a cost incurred by the Canadian
health care system and time is consumed in the management of CRNMB event when a
patient interaction occurs. Using latest effectiveness and Canadian cost data, our CEA
found that PGx-based warfarin is cost-effective at a lower WTP threshold than previously
reported and apixaban is the recommended DOAC in the treatment of AF patients.
Our CEA finds that apixaban is cost-effective at higher WTP thresholds than in most
published US and Canadian studies. Our analysis included baseline cost of living and
non-event death and reported higher lifetime accrued costs and incremental costs than
previous estimates. Our model improves on previous models by capturing intended and
unintended costs of introducing alternative OAC treatments that would be incurred by the
Canadian public healthcare payer. Moreover, the cost to gain one additional QALY under
apixaban increases from $60,649 when compared to standard warfarin to $64,853 when
compared to PGx-based warfarin. As such, our CEA improves on previous studies by
including all four OAC treatments in one analysis and allows decision makers to judge
the frontrunner strategy.
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3.4.4

Sensitivity Analyses

The deterministic analyses results show that there was high uncertainty around treatment
effectiveness. If low treatment effectiveness was assumed under PGx-based warfarin, the
risk of CRNMB and major hemorrhage increased, and standard warfarin offered a net
clinical benefit over PGx-based warfarin. On the other hand, if low rivaroxaban or
apixaban effectiveness was assumed, the DOACs were dominated by PGx-based
warfarin. Under low treatment effectiveness, the risks of ischemic stroke, myocardial
infarction and systemic embolism increased under DOAC treatment. The risk of CRNMB
and major hemorrhage also increased under rivaroxaban. In our analysis, rivaroxaban was
an undominated option only if low apixaban effectiveness was assumed or high
rivaroxaban effectiveness was assumed. In other cases, PGx-based warfarin and apixaban
were cost-effective at some willingness-to-pay thresholds.
In Canada, there is not one value set for willingness-to-pay threshold. In the past, a range
of values has been used in specific disease areas. For non-oncology drugs, a threshold of
$50,000/QALY has been considered a good value for money (69). Other expert opinion
suggests that a threshold of $100,000/QALY is the informal standard. The new 2020
Patented Medicine Prices Review Board (PMPRB) guidelines mention a specific
threshold of $150,000/QALY for pharmacoeconomic value assessments (70). When
compared to this threshold, both PGx-based warfarin and apixaban are viable OAC
strategies in Canada. Evidence strength and uncertainty also play a role in developing
grades of recommendation for adopting new technologies (71). The PSA results showed
that PGx-based warfarin had a higher probability of being cost-effective than apixaban
(51.5% vs 14.1%) at a WTP threshold of $50,000/QALY. At a WTP threshold of
$150,000/QALY, apixaban had a higher probability of being cost-effective than PGxbased warfarin (70.1% vs 5.7%).

3.5 Limitations
There are several limitations to our study. First, the estimated cost of the genotyping test
at the LHSC assumed optimal use of healthcare resources and staff time. The per patient
cost was calculated using the total number of tests conducted at the facility in 2018. The
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genotyping cost per patient may vary under other scenarios. Moreover, the marginal cost
of genotyping test did not include overhead costs such as the cost of facilities because the
test cost was obtained from a publicly funded university-affiliated hospital setting. In
addition, the lab manager fee to authorize test results and potential additional physician
billings due to tests were not included in our genotype test cost calculation. We tested the
sensitivity of our CEA results to varying PGx test costs in one-way sensitivity analysis
and found that PGx ICER values were sensitive to PGx test prices (Figure 3.3.2.4).
Second, our CEA included only direct medical care costs that were relevant from the
Canadian public healthcare payer perspective. A cost-utility analysis incorporating
indirect costs may decrease the estimated ICER values. If the costs of lost productivity,
absenteeism, presenteeism and unpaid care incurred by the patients are included, the
lifetime costs under standard warfarin care may increase and make alternative treatment
strategies more attractive.
Third, the relative effectiveness parameters of DOACs compared to standard warfarin
care were obtained from a study on indirect comparisons using a competing risks network
meta-analysis (24). PGx-based warfarin effectiveness parameters were obtained from a
single large double-blinded North American RCT (the COAG trial) (23). This trial
determined standard warfarin dosing using a clinical algorithm, which included body
surface area, age, African-American race, target INR, amiodarone use, smoking status
and a diagnosis of deep vein thrombosis/pulmonary embolism. However, current clinical
practice may not follow this dosing algorithm for standard warfarin. The genotype-guided
algorithm used these variables as well in addition to patient genotype. Accordingly, this
trial was designed to show the added value of the genotype in addition to known clinical
covariates, and may not represent standard warfarin care typically applied by health care
providers.
Fourth, the hazard ratio of CRNMB events under apixaban, rivaroxaban and PGx-based
warfarin were obtained from single RCTs (23,32,39). Several definitions of clinically
relevant non-major bleeding events exist in the published literature. Bahit et al. (2017)
identified CRNMB events as any acute or subacute clinically overt bleeding that did not
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satisfy the criteria for major bleeding by the International Society on Thrombosis and
Hemostasis (ISTH), the latter defined as a bleeding that led to a “hospital admission for
bleeding, physician-guided medical or surgical treatment for bleeding or change in
antithrombotic therapy (including study drug) due to bleeding” (32). The definition of
minor bleeding in the literature is even more ambiguous, and was classified as any
clinically overt bleeding that did not meet the criteria for either major or clinically
relevant non-major bleeding. Bahit et al. (2017) assessed the incidence of non-major
bleeding (including minor and CRNMB events) using patient-level data obtained from
the ARISTOTLE trial (32). Similarly, patients were assessed by the Kimmel et al. (2014)
and Patel et al. (2011) trial personnel to identify CRNMB events as per ISTH criteria
(23,39). As such, we can be reasonably confident in their classification of these events.
Despite these limitations, clinically relevant non-major bleeding events are important
patient-centric outcomes and may influence the quality of life adversely (72). CRNMB
events can lead to OAC discontinuation, which increases the risks of ischemic stroke and
death. In the ARISTOTLE trial, about 4.4% of AF patients who had a non-major
bleeding permanently discontinued anticoagulation therapy. As such, CRNMB events are
important drivers of physician-prescribing behaviour. Thus, we incorporated treatment
and cost differences in managing CRNMB events using best available evidence at this
time. However, given the ambiguous and overlapping definitions of CRNMB in the
literature, more data on the incidence and management of CRNMB for patients on
different anticoagulation strategies would improve future CEAs.
Fifth, the acute care costs of adverse events included the average hospitalization and
emergency costs. The acute care costs estimated from the ICES databases do not include
physician billing because an appropriate algorithm to capture these costs was not
available. However, we expect these costs will have a relatively small impact on the
results because the number of adverse events across treatment strategies is not too high.
We also did not capture downstream costs related to complications. For example, a
gastrointestinal (GI) bleed may precipitate from a bowel cancer. In this case, a
subsequent surgery care cost will be incurred by the healthcare system. However,
colorectal cancer complicated by GI bleeding in anticoagulated patients with AF are rare.
A recent study by Rasmussen et al. (2020) investigated the risk of colorectal cancer
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among AF patients aged 66 years and older. They reported an absolute 1-year colorectal
cancer risk of 4%-8% among patients with a lower GI bleed (73). The annual rate of
lower GI bleed among AF patients on warfarin in Ontario ranged from 4.6% in the first
month of anticoagulation to 1.2% for the rest of 5-years of follow-up in a populationbased study (27). Because the prevalence of colorectal cancer among lower GI bleeding
cases is relatively low, we assumed that the average cost of complications by colorectal
cancer will not have a substantial impact on the average cost of GI bleeding across
treatment strategies. Moreover, anticoagulation may lead to an earlier diagnosis of GI
cancer, which may reduce costs for subsequent care, but it might also increase costs.
Downstream costs may have an impact in tipping the scales in favour or against OAC
treatments if the ICER values were close to the general WTP thresholds, which are not
found to be the case here. Finally, our CEA focuses on cost differences driven by OAC
treatments.
Sixth, our CEA attempted to capture average acute care costs incurred by the Canadian
healthcare system using administrative databases, where feasible. We assumed that eventspecific acute care costs will be the same. However, there might be differences in the
severity of adverse events for patients on different OAC treatments. Our analysis does not
adequately account for the reduced risk of mortality under the DOACs. Moreover, we
removed non-OAC medication costs from ongoing care costs because our analysis
focused on OAC-related drug costs. However, higher OAC effectiveness may decrease
other medication costs. Cost data specific to OAC strategies may improve future CEAs.
In the face of limited published data, our estimates for CRNMB quantified costs relied on
healthcare resource use based on expert opinion. It is important to note that healthcare
response and resource use may vary in other settings.
Seventh, the risks of intracranial hemorrhage, transient ischemic attack, systemic
embolism and myocardial infarction were assumed to be the same for PGx-based and
standard warfarin care. Existing RCTs comparing PGx-based and standard warfarin care
have low event rates and are not powered to detect a significant difference for these
adverse events.
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Finally, this CEA makes long-term projections based on short-term clinical evidence and
clinically informed assumptions about plausible treatment pathways and transitions
between health states. Moreover, the patient profiles in clinical trials may not be the same
as those observed in real world patients. Consequently, the treatment effectiveness is
generally lower than efficacy. In routine-care, the plasma concentrations of DOACs
among patients are highly variable as compared to the variation observed in clinical trials
(74). The PSA acceptability curves showed that there was considerable parameter
uncertainty in our model. Nonetheless, in this model, the highest quality of effectiveness
data from meta-analysis of RCTs or single RCT with low confounding were used.
It is also important to note that our model is not designed for patients who switch or
permanently discontinue therapy. Additionally, our model does not consider patient
adherence or a no treatment option for patients with very low stroke risk or patients at
high mortality risk due to comorbidities other than AF. Future research is warranted for
these specific patient populations.

3.6 Strengths
Our findings add to the existing scientific knowledge in several ways. Contrary to current
medical practice and physician prescribing behaviour, the last two Canadian studies
recommended dabigatran 150 mg based on its cost-effectiveness. Since then, dabigatran
at this dose has been shown to increase the risk of gastrointestinal bleeds and dyspepsia.
Moreover, physicians prefer to prescribe apixaban or rivaroxaban over dabigatran for AF
patients in Canada (9). We excluded dabigatran from our analysis because of its limited
uptake in current clinical practice. Previous CEAs also estimated costs of apixaban and
rivaroxaban using literature-based data and showed that base case results were sensitive
to drug costs. Our CEA evaluated the cost-effectiveness of oral anticoagulation therapies
using most costs obtained from the Ontario population. A notable strength of our CEA is
that we included clinically relevant non-major bleeding events in addition to major
hemorrhagic and thromboembolic events to capture more comprehensively all relevant
risk and cost differences between treatment strategies. Our CEA improves on previous
studies by establishing the cost components of CRNMB using trial data and expert
opinion. Moreover, we incorporated clinically relevant adverse events without making
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explicit assumptions between INR ranges and adverse events. Finally, by comparing
standard warfarin care, PGx-based warfarin care, apixaban and rivaroxaban in one CEA,
we made it easy for healthcare decision makers and stakeholders to judge the frontrunner
anticoagulation strategy among all four treatments available for AF patients in Canada.
Our study shows the importance of including all available treatment strategies in the CEA
analysis. Our results show that excluding strategies can change the cost-effectiveness
frontier, which may lead to decision-making based on incomplete information. As such,
there must be strong justifications for excluding strategies in a cost-effectiveness
analysis.

3.6.1 Excluded alternatives: Dabigatran etexilate and Edoxaban
Although dabigatran etexilate belongs to the same class of drugs as apixaban and
rivaroxaban, dabigatran treatment is not being evaluated in this CEA because of lower
prescription numbers and some safety concerns. Specifically, two standard doses of
dabigatran are usually prescribed; 110 mg or 150 mg twice daily (4). Dabigatran 110 mg
has been shown to be non-inferior to warfarin in reducing the risk of stroke and systemic
embolism. However, dabigatran 110 mg has been found to be a safer alternative to
warfarin because it reduces the risk of major bleeding by ~20%. In contrast, dabigatran
150 mg has been found to be superior to warfarin by reducing the risk of ischemic stroke,
hemorrhage and systemic embolism by ~34%. However, although dabigatran 150 mg
reduces the risk of intracranial hemorrhages, gastrointestinal hemorrhages are more
common with high-dose dabigatran as compared to warfarin. Moreover, there is a nonsignificant increase in the risk of myocardial infarction with dabigatran as compared to
warfarin. Furthermore, dyspepsia (indigestion) is another common adverse event
associated with dabigatran use. In the RE-LY trial (n=18,113), about 11.8% of patients
on dabigatran 110 mg and about 11.3% of patients on dabigatran 150 mg suffered
dyspepsia as compared to 5.8% of patents on warfarin (P<0.001 for both comparisons)
(4). Moreover, physicians do not seem to prefer prescribing dabigatran for AF patients.
Since the approval of apixaban and rivaroxaban under the provincial formulary, a trend
towards declining number of dabigatran prescriptions for stroke prevention among AF
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patients is documented in Ontario (9). For these reasons, dabigatran is not considered as
an oral anticoagulant alternative in this CEA.
Our CEA also does not evaluate edoxaban because there is limited data on its
effectiveness and complications. Edoxaban is a relatively new anticoagulant that was
approved by Health Canada in November 2016 and thus not yet widely prescribed in
current clinical practice. Future studies should consider edoxaban if it becomes another
alternative treatment strategy for patients with AF.

3.7 Conclusions
As compared to standard warfarin care, PGx-based warfarin, apixaban and rivaroxaban
were more effective and expensive than standard warfarin care. However, PGx-based
warfarin care improved health benefits by only a small margin. Moreover, rivaroxaban
was not as effective in improving QALYs as apixaban and was associated with higher
costs. Consequently, apixaban dominates rivaroxaban. The incremental cost incurred
under apixaban therapy to gain one additional QALY is considered generally acceptable
at the willingness-to-pay thresholds of $65,000/QALY gained or higher. On the other
hand, the incremental cost to gain one additional QALY under PGx-based warfarin is
cost-effective at WTP thresholds of $20,000/QALY gained or higher. Given the 2020
PMPRB guidelines (70) comparing incremental cost-utility ratio values to a threshold of
$150,000/QALY, both PGx-based warfarin and apixaban may demonstrate two viable
strategies for Canada. However, structural limitations need to be considered before
incorporating PGx-based warfarin care into routine clinical practice and on a wider scale
as it is currently limited to specialty clinics. Moreover, if one argues that the most costeffective strategy is the one closest to the WTP threshold, then, apixaban maximizes
average patient health gain given the public healthcare payer’s willingness to pay in
Canada. We found that apixaban offers the best balance between efficacy and safety and
has a high probability of being cost-effective for AF patients in Canada at a WTP
threshold of $150,000/QALY.
For AF patients who are eligible for DOAC treatment, apixaban remains a more feasible
treatment option than PGx-based warfarin care. For patients who are ineligible for DOAC
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treatment, such as those with mechanical heart valves or poor renal function, PGx-based
warfarin care may be the only treatment option for anticoagulation. However, the results
of our CEA are not applicable to this patient population and no conclusions can be made.
Future CEA for this specific target population is needed before any conclusions can be
drawn.
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Chapter 4 - Conclusions
Atrial fibrillation (AF) is a common cardiac arrhythmia among seniors (65+ years old)
and is associated with high morbidity and mortality risks. AF increases the risk of stroke
by 3-5 times and all-cause mortality by 3.5-fold (1). In addition, stroke complications can
leave patients with physical disabilities, poor quality of life and in need of constant
nursing and long-term care (2,3). Not only does AF entail substantial burden on patient
health, it also imposes a huge financial strain on the Canadian healthcare system. In
Ontario, hospitalizations due to AF-related ischemic stroke or transient ischemic attack
cost about $19,113 per admission and have the longest in-hospital stay of 20.2 days (1).
In addition, hospitalizations due to AF-related hemorrhages are the costliest hospital
admissions, with an average cost of $26,746 per admission. Since AF risk increases with
ageing, the prevalence and burden of AF is expected to increase with the ageing of the
Canadian population in the foreseeable future and beyond (2).
Several oral anticoagulation therapies are available to mitigate the risks of AF. Warfarin,
also commercially known as Coumadin, is a commonly prescribed anticoagulant drug to
treat AF patients (4). It can reduce the risk of stroke by 66% if the drug’s therapeutic
effect is achieved, which is defined as having an International Normalized Ratio (INR) of
2-3 (4). Although warfarin has been widely prescribed in the past few decades, there are
many challenges associated with standard warfarin therapy. Warfarin therapy is known to
have a narrow therapeutic window, delayed pharmacodynamic response and interpatient
genetic variability in drug metabolism and response (5,6). In current clinical practice,
warfarin patients must initially undergo an adjustment period during which the optimal
dose for the individual is determined through trial and error and guided by repeated blood
tests (4). During this adjustment period, patients may experience a high risk of adverse
events if inappropriate dose is prescribed.
There is a wide interpatient variability observed in warfarin dose requirements. About
30% of this variability can be attributed to single nucleotide polymorphisms (SNPs) in
three pharmacogenes encoding the following enzymes: (i) cytochrome P450 (CYP) 2C9
involved in S-warfarin metabolism (gene CYP2C9), (ii) vitamin K epoxide reductase
(gene VKORC1), the pharmacological target, and (iii) CYP4F2 (gene CYP4F2) involved
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in vitamin K metabolism (7). Individuals with one or all of these mutations experience a
longer and riskier warfarin dose adjustment period (4). Pharmacogenomics (PGx) based
warfarin therapy tailors the drug dose for each patient using his/her genotypic
information in conjunction with demographic and clinical variables such as age, weight,
height, smoking status and more (8). PGx-based warfarin care offers several benefits over
standard warfarin care; it has been shown to increase the efficiency with which the
therapeutic anticoagulation effect is achieved among patients and reduce risk of adverse
events (9–11). Recent meta-analyses show that PGx-based warfarin dosing reduces the
risk of major hemorrhage by 30-60% (9–11). However, PGx-based warfarin care requires
an upfront cost of genotyping test. Thus, it is important to assess if the upfront cost of
genotyping test outweighs the benefits.

To date, published studies on the cost-effectiveness of PGx-based warfarin therapy
compared to standard warfarin therapy have produced conflicting results with 3 studies
finding PGx cost-effective, 5 finding PGx not cost-effective and 4 being inconclusive
(12). The published cost-effectiveness analyses (CEAs) have compared standard warfarin
dosing with genotype guided warfarin dosing for a hypothetical cohort of senior AF
patients between the ages of 45-75 years. Patrick et al. (2009) found that PGx-based
warfarin care could be cost-effective in the US if the time in therapeutic range (TTR) was
increased by 5-9% in the first 3 months of initiating therapy (13). In Canada,
Nshimyumukiza et al. (2013) found PGx-based warfarin care was not cost-effective at
the willingness-to-pay (WTP) threshold of $50,000 per quality-adjusted life-year
(QALY) gained (14). In contrast, a more recent CEA by Verhoef et al. (2016) found that
PGx-based warfarin care was cost-effective as compared to standard warfarin care in the
UK and Sweden (15). There is considerable uncertainty about the cost-effectiveness of
PGx-based warfarin care relative to standard warfarin care in the published literature; the
results seem to vary by population and geographical region.
In Canada, direct oral anticoagulants (DOACs) such as apixaban and rivaroxaban were
recently approved for funding for stroke prophylaxis among AF patients by the Ontario
Ministry of Health and Long-Term Care (MOHLTC) (16). Studies have shown that
DOACs offer several advantages over warfarin therapy such as a more predictable
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therapeutic effect, require no routine INR monitoring, demonstrate increased
effectiveness in stroke prevention and are associated with lower risks of hemorrhagic
adverse events as compared to warfarin (17). The improved safety of DOACs may
translate into reduced financial strain on the Canadian healthcare system. However, the
unit cost of DOACs is more than 20 times the cost of warfarin (18). Thus, it is important
to carefully assess the cost-effectiveness of anticoagulation therapy with DOACs such as
apixaban and rivaroxaban as compared to warfarin therapy.
To date, published studies on the cost-effectiveness of DOACs such as apixaban and
rivaroxaban compared to warfarin therapy in the US, Europe and Canada have generally
produced conclusions in favour of DOACs (15,19–21). Among apixaban and
rivaroxaban, apixaban is often found to be the most cost-effective DOAC when compared
to standard warfarin care. However, it has also been shown that the cost-effectiveness of
DOACs is sensitive to drug prices and anticoagulation control under warfarin care. For
example, Jarungsuccess et al. (2014) found that dose-adjusted warfarin therapy could be
cost-effective option in Thailand if the drug unit costs decreased by 85% (22). Similarly,
You et al. (2013) concluded that the DOACs could be cost-effective in the US if the TTR
under standard warfarin care was below 60% (20). Although, DOACs have been shown
to be cost-effective alternative to warfarin care in Canada, Coyle et al. (2013) and
Nshimyumukiza et al. (2013) found that dabigatran prescribed at 150 mg twice daily was
the recommended DOAC based on its cost-effectiveness (14,21). However, latest clinical
effectiveness data show that high-dose dabigatran is associated with increased risks of
gastrointestinal hemorrhages and dyspepsia (17). These adverse events were not
considered by Coyle et al. (2013) and Nshimyumukiza et al. (2013), thus requiring an
updated cost-effectiveness evaluation of DOACs from a Canadian healthcare payer
perspective.
This CEA investigated the cost-effectiveness of PGx-based warfarin, apixaban and
rivaroxaban as compared to standard warfarin care from the Canadian public healthcare
perspective using literature-based effectiveness data and most costs from the ICES data
repository. A decision-analytic Markov model was developed to compare the lifetime
costs and quality-adjusted life years (QALYs) or life-years (LYs) gained by a
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hypothetical cohort of newly diagnosed AF patients aged 65 or older. Deterministic and
probabilistic sensitivity analyses were undertaken to study the influence of uncertainty in
model parameters on the incremental cost effectiveness ratio (ICER).
The base case results of this CEA indicate that the PGx-based warfarin and DOACs
produce higher QALYs than standard warfarin care but at higher costs. Among
undominated strategies, PGx-based warfarin increased QALYs by 0.03 units (~11 days)
and costs by $583; it costed about $17,727/QALY gained. Apixaban increased QALYs
by 0.34 units (~4.08 months) and costs by $21,790; it costed about $64,853/QALY
gained. Rivaroxaban was dominated by apixaban. Deterministic sensitivity analysis
showed high uncertainty associated with treatment effectiveness. The ICER value for
PGx-based warfarin was also sensitive to PGx test price and age of OAC initiation. PGxbased warfarin had a higher probability of being cost-effective than apixaban (51.5% vs
14.1%) at a WTP threshold of $50,000/QALY. At a WTP threshold of $150,000/QALY,
apixaban had a higher probability of being cost-effective as compared to PGx-based
warfarin (70.1% vs 5.7%).
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Appendix A: Sample Calculations
To specify probability distributions for the probabilistic analysis, the uncertainty (95%
confidence interval (CI)) around the mean estimate was investigated.
A.1

Parameterizing using Normal distribution

If the 95% CI was relatively symmetric around the mean estimate, we parameterized
using normal distribution.
Table A.1: Calculations carried out to draw normal distribution around hazard ratios for
effect of history of event on future adverse event (example).
Difference Difference
Future
95% 95%
Hazard
between
between
Standard
adverse
CI
CI
Distribution
ratio
LB and
UB and
error *
event
LB
UB
Mean
Mean
Effect of ischemic stroke on future events
Major
1.39
1.27 1.52 0.12
0.13
0.06
Normal
hemorrhage
ICH
1.64
1.39 1.94 0.25
0.30
0.14
Normal
CI, confidence interval; LB, lower bound; UB, upper bound
*Standard error was the average difference between mean and 95% CI divided by 1.96
A.2

Parameterizing using LogNormal distribution

In some cases, the 95% CI was not symmetric around the mean. In these cases, we
investigated and confirmed normality assumption on the logarithmic scale and used a
LogNormal distribution.

Table A.2.a: The 95% CIs around hazard ratios (HRs) of PGx-based warfarin
effectiveness were not symmetric around the mean estimates (example).
Difference
Difference
Hazard
95% CI
95% CI
Adverse event
between LB between UB
ratio
LB
UB
and Mean
and Mean
Major hemorrhage 0.41
0.13
1.31
0.28
0.9
CRNMB
0.62
0.3
1.27
0.32
0.65
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Table A.2.b: Calculations carried out on HRs and 95% CIs presented in Table A.2.a to
confirm normality on logarithmic scale and parameterize using LogNormal distribution.
95%
95%
Mean
Difference Difference
CI
CI
Adverse
of
from
from
Standard
LBUBDistribution
event
logs,
mean to
mean to
error*
log
log
µ
LB
UB
scale
scale
Major
-0.89 -2.04 0.27
1.15
1.16
0.59
LogNormal
hemorrhage
CRNMB
-0.48 -1.20 0.24
0.73
0.72
0.37
LogNormal
CI, confidence interval; LB, lower bound; UB, upper bound
*Standard error was the average difference between mean and 95% CI divided by 1.96
A.3

Parameterizing using Beta distribution

To ensure the correct support for acute (30-day) mortality and proportions, we used beta
distributions.
Table A.3: Calculations carried out to draw beta distribution around acute mortality after
an ischemic stroke estimated from the Tung et al. (2015) study (1) (example).
No. of
total
No. of
Acute
95% CI 95% CI
ischemic acute
death
Distribution
alpha beta
LB
UB
stroke
deaths (%)
cases
6006
1639
27.29
Beta
1639
4367 26.17% 28.42%
No., number; CI, confidence interval; LB, lower bound; UB, upper bound
alpha= No. of acute deaths; beta= No. of total ischemic stroke cases - No. of acute deaths
A.4

Parameterizing using Gamma distribution

To ensure the correct support for skewed costs, we used gamma distributions.
Table A.4: Calculations carried out to draw gamma distribution around acute care cost
after major hemorrhage (example).
Adverse
event

Sample Mean
size, N Cost

Standard Standard
alpha
deviation error

beta

Non-fatal
major
947
3126
4593
149
438
7
hemorrhage
CI, confidence interval; LB, lower bound; UB, upper bound
Standard error=Standard deviation/square- root(Sample size, N)
alpha=(mean cost2/standard error2); beta=(standard error2/mean cost)

95%
CI LB

95%
CI UB

2840

3425
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A.5

Major hemorrhage rates

Major hemorrhage was a weighted average of upper and lower gastrointestinal and other
hemorrhages. In Gomes et al. (2013), Table 2, the 95% confidence intervals were nearly
symmetric around the mean estimates (2). And so, we assumed normal distribution. The
standard deviation of mean of rates is the sum of variances (assuming independent
random variables).
Table A.3: Estimates of the rate of major hemorrhage during first month of therapy and
distribution parameters (example).
Difference Difference
Annual 95% 95%
Type of
between
between
Standard Variance
rate
CI
CI
hemorrhage
LB and
UB and
deviation* **
(%/PY) LB
UB
Mean
Mean
<=30 days
Upper
4.00
3.80 4.20 0.20
0.20
0.10
0.0104
gastrointestinal
Lower
4.60
4.40 4.90 0.20
0.30
0.13
0.0163
gastrointestinal
Other
4.70
4.50 5.00 0.20
0.30
0.13
0.0163
Mean rate
13.30
(%/PY)
Sum of variances
0.0430
Square root of sum of variance
0.2072
PY, person-years; CI, confidence interval; LB, lower bound; UB, upper bound
*Standard deviation was the average difference between mean and 95% CI divided by
1.96
**Variance is the square of standard deviation

A.6

Costs

A.6.1 Estimating baseline age-specific health care expenditure
The 2017 Ontario expenditure per year for both sexes were obtained from CIHI website
(Table E.1.20.2-Estimate of total per capita provincial/territorial government health
expenditures) (3). The age-specific probability of dying was obtained from STATCAN
website (Table: 13-10-0114-01) (4). Tanuseputro et al. (2015) reported the average age-

117

specific costs incurred by the Ontario population in the last year of death (5). We
assumed the following formula in the calculation of CIHI-Expenditure per capita.
CIHI-Expenditure per capita =
(Baseline age-specific health care expenditure)*(1-Probability of dying) + (Cost in last
year of death)*(Probability of dying)
Baseline age-specific health care expenditure =
[CIHI-Expenditure per capita - (Cost in last year of death)*(Probability of dying)]/(1Probability of dying)
Then, we increased the baseline age-specific health care expenditure by an incremental
cost of AF of $3,898.33 (2017 CAD).
A.6.2 Estimating incremental cost of AF
Kim et al. (2010) reported the incremental cost incurred by ~71-year-old AF patients
using a matched US cohort (6). About 57% of patients in the AF cohort were on warfarin
and only 5% of control non-AF patients were on warfarin, which is reasonable given we
want the incremental costs incurred by AF patients as compared to general population.
We extracted the costs attributed to AF-related hospitalization (inpatient costs) and
outpatient medical services (ER visits, physician visits, laboratory services and other
outpatient services). In addition, we extracted the non-CVD costs for inpatient
hospitalizations and outpatient services. We did not extract other CVD costs because
those events were modelled separately in our Markov model. The US costs were
converted to CAD costs using purchasing power parity of 0.8 (7). Costs were adjusted to
2017 using STATCAN website, CANSIM Table:18-10-0005-01 (8).
The CIHI-expenditure (Table E.1.20.2) shows that the total cost per 71-year-old is
$8,335.14 (2017 CAD). Table 2 in Kim et al. (2010) reported that a 71-year-old non-AF
patient costs about $11,965 (2008 USD). We compared the reported costs of non-AF US
patient to Canadian patient and adjusted for percent inflation due to US healthcare
system.
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A.6.3 Acute care cost of CRNMB
Table A.6.3: Estimating acute care cost of CRNMB using Bahit et al. (2017) and expert
opinion (9,10).
Sub-type
Cost components Cost ($)
Notes
Proportions
Each CRNMB encounter leads to a general
consultation with a GP/FP or a specialist.
Fixed cost of
Based on expert opinion, the ratio of GP/FP
consultation
97.15
to specialist is 3:1. Using this information,
(A005, A135)
the average fixed cost of an encounter with
a healthcare professional is calculated.
Hematuria
0.164 Bahit et al. (2017) (9)
Common
Based on expert opinion, the average cost of
10.00
antibiotics
antibiotics is ~$10. (10)
Pharmacy
Average pharmacy dispensing fee across
11.31
dispensing fee
Ontario. (11)
Urology
consultation
80.00
(A355)
If patient is referred to a specialist.
Cystoscopy
71.00
(Z606)
Includes cost of antibiotics and pharmacy
Low end cost
21.31
0.6 dispensing fee. The sub-type proportion was
expert’s opinion.
Includes cost of urology consultation and
High end cost
151.00
0.4 cystoscopy. The sub-type proportion was
expert’s opinion.
Total sub-type
Weighted average of low- and high-end cost
170.34
cost
+ fixed cost of consultation
Epitaxis
0.148 Bahit et al. (2017) (9)
Anterior packing
15.35
(Z315)
Cauterization
11.50
(Z314)
Posterior packing
35.50
(Z316)
ENT consult
80.00
(A245)
Includes cost of anterior packing and
Low end cost
26.85
0.8 cauterization. The sub-type proportion was
expert’s opinion.
Includes all cost components. The sub-type
High end cost
142.35
0.2
proportion was expert’s opinion.
Total Sub-type
Weighted average of low- and high-end cost
$147.10
cost
+ fixed cost of consultation
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Non-major GI
bleed
Colonoscopy
(Z496+E74O+E7
41+E747+E705)
Gastroenterology
consult (A415)

197.21

Sum of Cost

354.21

Total Sub-type
cost

451.36

Non-major
CRNMB

97.15

Total Sub-type
cost
Total CRNMB
cost

0.133 Bahit et al. (2017) (9)

157.00
All patients who come-in for a non-major
1 GI bleed are administered a colonoscopy
and have a GI consult.
Weighted average of low- and high-end cost
+ fixed cost of consultation
Only the fixed cost of consultation is
0.555 accrued for all other non-major bleeding
events.

97.15
Weighted average cost per patient by
proportions of CRNMB sub-types

$163.66

A.6.4 Anticoagulation drug therapy costs
Table A.6.4: Calculations carried out to estimate drug therapy costs.
Unit costs of resource utilization
Cardiologist consultation fee (billing
code A605)
Physician consultation fee (billing
code A005)
Consultation fee for Prothrombin
time (PT/INR) lab test (billing code
G031)
Anticoagulant supervision fee - longterm management of warfarin via
telephone advice (billing code G271)
Prothrombin time (PT/INR) lab test
(billing code L445)
Average pharmacy dispensing fee

Mean Cost
157.00
77.20
6.20

Schedule of Benefits for Physician
Services (12)

12.75
2.66
11.31

Monthly drug costs (Summary)
Monthly cost of warfarin drug (5mg
qd)
Monthly cost of apixaban drug (2.5-5
mg bid)

Source

Schedule of Benefits for
Laboratory Services (13)
(11)

Notes
2.03
98.02

Unit cost obtained from ODB
Formulary (14) and multiplied
with the monthly dose regime.
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Monthly cost of rivaroxaban (15-20
mg qd)
Estimating monthly therapy costs
Monthly cost of warfarin therapy
(1st month)
Cardiologist consultation fee
(billing code A605)
Physician consultation fee (billing
code A005)
Monthly cost of warfarin drug
(5mg qd)

86.10

282.98
157.00
77.20
2.03

Prothrombin time (PT/INR) lab
test (billing code L445)

10.64

Consultation fee for Prothrombin
time (PT/INR) lab test (billing
code G031)

24.80

Average pharmacy dispensing fee

11.31

Monthly cost of warfarin therapy
(2-12th month)

*assumed one specialist visit
based on expert opinion (15)
Unit cost obtained from ODB
Formulary (14)
*assumed one PT/INR test per
week in the first month as per
warfarin dosing protocol (16)
*assumed each PT/INR test
elicited a PT/INR lab test
consultation fee
(11)

32.58

Total cost over 11-month period

358.42

Physician consultation fee (billing
code A005)

159.37

Anticoagulant supervision - longterm, telephone advice (billing
code G271)

60.65

The 11-month cost was
calculated and divided into
monthly costs to reduce bias in
costs because the exact timing of
visits, consultation and PT/INR
tests is not known.
Schulman et al. (2010) reported a
total of 235 healthcare contacts
for 96 patients over 3-month
period and 23% of these
interactions were site visits with
physician consultations at a
community-based family
physician. Thus, an average of
~2.06 physician consultations
were assumed over the 11-month
period. (17)
Schulman et al. (2010) reported a
total of 235 healthcare contacts
for 96 patients over 3-month
period and 53% of these
interactions occurred via
telephone at a community-based
family physician. Thus, an
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average of ~4.76 telephone
interactions were assumed over
the 11-month period. (17)

11- Month cost of warfarin drug
(5mg qd)

22.28

Prothrombin time (PT/INR) lab
test (billing code L445)

21.28

Consultation fee for Prothrombin
time (PT/INR) lab test (billing
code G031)

49.60

Average pharmacy dispensing fee

45.24

Monthly cost of warfarin therapy
(>12th month)

Total annual cost

Cardiologist consultation fee
(billing code A605)
Physician consultation fee (billing
code A005)
12-Month cost of warfarin drug
(5mg qd)

Unit cost obtained from ODB
Formulary (14)
A total of 8 PT/NR tests were
assumed; 1 PT/INR test/month
for 2-6 months and then, 1
PT/INR test every other month
for 7-12 months as recommended
by the Warfarin Dosing Protocol.
(16)
Each PT/INR test was assumed to
incur a PT/INR test consultation
fee (8 PT/INR consultations in
total over 11-month period).
A total of 4 pharmacy claims left
in one year after first month.

26.48

317.71

157.00
77.20

The annual cost was calculated
and then, divided into monthly
cost because the timing of visits,
consultations and PT/INR test is
not known.
*assumed one specialist visit
based on expert opinion (15)

24.30

(14)

Prothrombin time (PT/INR) lab
test (billing code L445)

2.66

*assumed one PT/INR test per
year for event-free patients
because warfarin therapy
involves routine PT/INR
monitoring

Average pharmacy dispensing fee

56.55

(11)

Monthly cost of apixaban therapy
(1st month)

343.53

Cardiologist consultation fee
(billing code A605)

157.00

*assumed one specialist visit
based on expert opinion (15)
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Physician consultation fee (billing
code A005)
Monthly cost of apixaban drug
(2.5-5 mg bid)
Average pharmacy dispensing fee
Monthly cost of apixaban therapy
(2-12th month)
Total cost over 11-month period
11- Month cost of apixaban drug
(2.5-5 mg bid)
Average pharmacy dispensing
fee
Monthly cost of apixaban therapy
(>12th month)
Total annual cost
Cardiologist consultation fee
(billing code A605)
Physician consultation fee (billing
code A005)
12-Month cost of apixaban drug
(2.5-5 mg bid)
Average pharmacy dispensing fee
Monthly cost of rivaroxaban
therapy
(1st month)
Cardiologist consultation fee
(billing code A605)
Physician consultation fee (billing
code A005)
Cost of rivaroxaban drug (10-20
mg qd)
Average pharmacy dispensing fee
Monthly cost of rivaroxaban
therapy
(2-12th month)

77.20
98.02

(14)

11.31

(11)

102.13

*includes the cost of drug only
(14)

1,123.42
1,078.18
45.24

(11)

122.25

1,466.94

157.00
77.20

The annual cost was calculated
and then, divided into monthly
cost because the timing of visits,
consultations is not known.
*assumed one specialist visit
based on expert opinion (15)

1176.19

(14)

56.55

(11)

331.61
157.00
77.20
86.10
11.31
82.70

Total cost over 11-month period

992.34

11- Month cost of rivaroxaban
drug (10-20 mg qd )

947.10

*assumed one specialist visit
based on expert opinion (15)
(14)
(11)

*includes the cost of drug only
(14)
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Average pharmacy dispensing fee
45.24
Monthly cost of rivaroxaban
therapy
(>12th month)
Total annual cost

(11)

110.33

1,323.95

The annual cost was calculated
and then, divided into monthly
cost because the timing of visits,
consultations is not known.

Cardiologist consultation fee
157.00
(billing code A605)
*assumed one specialist visit
based on expert opinion (15)
Physician consultation fee
77.20
(billing code A005)
12-Month cost of rivaroxaban
drug
1033.20
(14)
(10-20 mg qd)
Average pharmacy dispensing fee
56.55
Note: Unit costs were multiplied with the respective estimated healthcare resource use to
obtain costs.
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Appendix B: Supplementary PSA Results

Figure B.1: Cost-effectiveness acceptability curves for patients initiating OAC treatment
at the age of 75 years.
At the WTP threshold of $50,000/QALY gained, PGx-based warfarin was the costeffective treatment in 49% of the iterations, followed by standard warfarin in 47.7% of
iterations, apixaban in 2.6% of iterations and rivaroxaban in about 0.7% of iterations. At
the WTP threshold of $100,000/QALY gained, PGx-based warfarin was cost-effective in
42.9% of the iterations, followed by apixaban in 33% of iterations, standard warfarin in
13.5% of iterations and rivaroxaban in 10.6% of iterations. At the WTP threshold of
$150,000/QALY gained, apixaban was cost-effective in 57.7% of the replications,
rivaroxaban in about 20.9% of iterations, PGx-based warfarin care in 18.3% of iterations
and standard warfarin care in only 3.1% of iterations.
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Figure B.2: Cost-effectiveness acceptability curves for patients with a history of Major
IS.
At the WTP threshold of $50,000/QALY gained, standard warfarin was the cost-effective
treatment in 64.3% of the iterations, followed by PGx-based warfarin in 32.2% of
iterations, apixaban in 1.7% of iterations and rivaroxaban in about 1.8% of iterations. At
the WTP threshold of $100,000/QALY gained, PGx-based warfarin was cost-effective in
36.6% of the iterations, followed by apixaban in 27.7% of iterations, standard warfarin in
19.8% of iterations and rivaroxaban in about 15.9% of iterations. At the WTP threshold
of $150,000/QALY gained, apixaban was cost-effective in 48.7% of the replications,
rivaroxaban in about 27.1% of iterations, PGx-based warfarin care in 19.5% of iterations
and standard warfarin care in only 4.7% of iterations.
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Figure B.3: Cost-effectiveness acceptability curves for patients with a history of Minor
IS.
At the WTP threshold of $50,000/QALY gained, standard warfarin was the cost-effective
treatment in 39.5% of the iterations, followed by PGx-based warfarin in 32.7% of
iterations, apixaban in 17.1% of iterations and rivaroxaban in about 10.7% of iterations.
At the WTP threshold of $100,000/QALY gained, apixaban was cost-effective in 50.5%
of the iterations, followed by rivaroxaban in 28.2% of iterations, PGx-based warfarin in
15% of iterations and standard warfarin in about 6.3% of iterations. At the WTP
threshold of $150,000/QALY gained, apixaban was cost-effective in 61.1% of the
replications, rivaroxaban in about 32.5% of iterations, PGx-based warfarin care in only
5% of iterations and standard warfarin care in only 1.4% of iterations.
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Figure B.4: Cost-effectiveness acceptability curves for patients with a history of TIA or
SEE.
At the WTP threshold of $50,000/QALY gained, PGx-based warfarin was the costeffective treatment in 54.5% of the iterations, followed by standard warfarin in 38% of
iterations, apixaban in 5,4% of iterations and rivaroxaban in about 2.1% of iterations. At
the WTP threshold of $100,000/QALY gained, apixaban was cost-effective in 44.1% of
the iterations, followed by PGx-based warfarin in 33.9% of iterations, rivaroxaban in
15.6% of iterations and standard warfarin in only 6.4% of iterations. At the WTP
threshold of $150,000/QALY gained, apixaban was cost-effective in 63.4% of the
replications, rivaroxaban in about 24.3% of iterations, PGx-based warfarin care in only
11.1% of iterations and standard warfarin care in only 1.2% of iterations.
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